<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":10715,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Kinetic Concepts, Inc. v. Smith & Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/6fbf8c218bec0e89de0d86ac94c15f96'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/6fbf8c218bec0e89de0d86ac94c15f96'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1I3EVM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I3EVM003">Previous Result: <span>Swygert v. Evergreen Packaging, Inc., CA...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1I3F06003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I3F06003">Next Result: <span>Stebbins v. Boone Cnty., Civil No. 12-30...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Kinetic Concepts, Inc. v. Smith &amp; Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed. Cir. 2012), Court Opinion'>
Kinetic Concepts, Inc. v. Smith &amp; Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Kinetic Concepts, Inc. v. Smith & Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I3E9Q003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Kinetic Concepts, Inc. v. Smith & Nephew, Inc.</div>
<div class='displayCitation'>104 U.S.P.Q.2d 1001</div>
<div class='displayCitation'>2012 BL 204409</div>
<div class='displayCitation'>688 F.3d 1342</div>
<div class='displayCitation'>bna a0d4c3y9g9</div>
<div class='displayCitation'>bna a0d4c4p6k6</div>
<div class='displayCitation'>bna a0d4u0j9d0</div>
<div class='displayCitation'>wkffecase:26270877</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I3E9Q003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Kinetic Concepts, Inc. v. Smith &amp; Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Kinetic Concepts, Inc. v. Smith &amp; Nephew, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1I3E9Q003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I3E9Q003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I3E9Q003" /><input id="title" name="title" type="hidden" value="Kinetic Concepts, Inc. v. Smith &amp; Nephew, Inc., 688 F.3d 1342, 104 U.S.P.Q.2d 1001 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="6fbf8c218bec0e89de0d86ac94c15f96" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I3E9Q003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%36fbf%38c%32%31%38bec%30e%38%39de%30d%38%36ac%39%34c%31%35f%39%36%2Fdocument%2FX%31I%33E%39Q%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/bcite/X1I3E9Q003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/bcite/X1I3E9Q003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/bcite/X1I3E9Q003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/related_content/X1I3E9Q003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1721688195075";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">688 F3d 1342</div>
<div class="cite" data-cite-type="ReporterOfDecisions">104 U.S.P.Q.2d 1001</div>
<div class="cite" data-cite-type="DocketNumber">2011-1105</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 204409</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
KINETIC CONCEPTS, INC., KCI Licensing, Inc., KCI USA, Inc., KCI Medical
Resources, KCI Manufacturing, and Medical Holdings Limited, Plaintiffs, and
Wake Forest University Health Sciences, Plaintiff-Appellant, v. SMITH &amp;
NEPHEW, INC., Defendant-Appellee.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1105.
</center></p>
<p><center>
August 13, 2012.
<span CLASS="page_no" data-cite="104 uspq 2d 1003" data-cite-type="ReporterOfDecisions" data-cite-pageno="1003" data-primary-citation="104 U.S.P.Q.2d 1001">[**1003]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926080" href="#headnote_ref_pq2-dec_926080">[1]</a> <span>Procedure &mdash; Jury trials </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.42" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.42">&#9658;410.42</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court hearing patent infringement action did not submit issue of obviousness to &ldquo;advisory jury&rdquo; under Fed. R. Civ. P. 39(c)(1), even though district court referred to jury as &ldquo;advisory,&rdquo;
since Rule 39(c)(1) advisory jury is available only in action that is not triable to jury as of right, whereas patent infringement actions must be tried to jury if demanded by party, since defendant did not request, and district court did not make, special findings required by Fed. R. Civ. P. 52 in all actions tried &ldquo;with an advisory jury,&rdquo; since defendant, rather than filing post-trial motion to have judgment amended under Rule 52(b), instead filed motion under Fed. R. Civ. P. 50, which governs &ldquo;judgment as a matter of law in a jury trial,&rdquo; and since defendant concedes that both district court and appellate court must defer to jury's explicit factual findings, which is inconsistent with use of Rule 39(c)(1) advisory jury.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926081" href="#headnote_ref_pq2-dec_926081">[2]</a> <span>Procedure &mdash; Jury trials </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.42" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.42">&#9658;410.42</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Judicial review &mdash; Standard of review &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.4607.09" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.4607.09">&#9658;410.4607.09</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Patent infringement plaintiff did not waive jury trial on any factual question, underlying issue of obviousness, that was not submitted to jury in interrogatory in Fed. R. Civ. P. 49 special verdict form, and federal district court was required to accept all of jury's implicit factual findings that were supported by substantial evidence, since district court, by including ultimate question of obviousness on special verdict form, implicitly required jury to make all factual determinations underlying that ultimate question; jury's explicit and implicit factual findings are reviewed on appeal for substantial evidence, and legal conclusion of obviousness is examined de novo to determine whether it is correct in light of factual findings that are adequately supported.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926082" href="#headnote_ref_pq2-dec_926082">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's conclusion that prior art references disclosing device for draining fluid from purulent wounds do not disclose treatment of wounds using negative pressure as required by asserted claims of patents in suit, even though infringement defendant's expert witnesses contended that references disclosed treatment of wounds within meaning of claims, since plaintiff offered expert testimony that purulent wounds described in references were abscess pockets that are not within definition of &ldquo;wound&rdquo; as that term is used in claims, and that use of device disclosed in references is discontinued when purulent wound has been cleaned of infection, whereas patented method and apparatus are used only after wound has been cleaned of infection, since references explain that use of negative pressure on or surrounding wound can be dangerous to patient, which amounts to &ldquo;teaching away,&rdquo;
since plaintiff presented additional testimony that device disclosed in references could not create adequate seal, and did not sustain pressure for period of time sufficient to &ldquo;treat&rdquo; wounds through negative pressure, since jury was free to make credibility determinations and believe witnesses it considered more trustworthy, and since, in light of jury&rsquo;s determination that defendant failed to prove obviousness, it must be inferred that jury found plaintiff's experts to be credible and persuasive on this point.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926083" href="#headnote_ref_pq2-dec_926083">[4]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's conclusion that prior art reference does not disclose methods and apparatus for treatment of wounds claimed in patents in suit, since all asserted claims require use of negative pressure to heal or treat wounds, since infringement plaintiff presented testimony that reference discloses seal around wound that is only &ldquo;relatively liquid tight&rdquo; and that has air gaps, and that reference thus does not create &ldquo;seal&rdquo; within meaning of claims, since jury also heard testimony that reference uses tubing system to medicate and drain wounds in order to promote healing generally, but that it does not disclose maintaining negative pressure to facilitate closure until wound has progressed to selected stage of healing, as claims require, since inventor of device described in reference testified that inventors of patents in suit had invented use of negative pressure for wound therapy and that he had not, and since, in light of jury&rsquo;s determination that defendant failed to prove obviousness, it must be inferred that jury found plaintiff's witnesses to be credible and persuasive on this point.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926084" href="#headnote_ref_pq2-dec_926084">[5]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's conclusion that prior art references describing system for treating wounds complicated by fistulae do not disclose treatment of wounds using negative pressure as required by asserted claims of patents in suit, even though infringement defendant presented testimony that disclosed system had been used to heal one patient using negative pressure, since term &ldquo;wound,&rdquo;
as used in claims, does not cover fistulae described in references, since plaintiff presented expert testimony that all patients mentioned in references had fistulae, that references therefore do not disclose treatment of &ldquo;wounds&rdquo; within meaning of claims, and that device disclosed in references did not use negative pressure to treat wounds, since references taught limiting of granulization, which is directly contrary to purpose of patents, since authors of references conceded that they did not publish anything about negative pressure wound therapy, and that they never suggested using disclosed device if drainage was unnecessary, since plaintiff presented additional testimony that drainage system disclosed in references was discontinued once fistula closed or substantial drainage for fistula ceased, regardless of state of wound healing, and since, in light of jury&rsquo;s determination that defendant failed to prove obviousness, it must be inferred that jury found plaintiff's witnesses to be credible and persuasive.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926085" href="#headnote_ref_pq2-dec_926085">[6]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Person of ordinary skill in art </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0902" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0902">&#9658;115.0902</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Less sophisticated level of skill in art generally favors determination of nonobviousness, and thus patentee, whereas higher level of skill favors finding of obviousness; in present case, in which jury found that infringement defendant failed to prove obviousness of inventions of patents directed to apparatus and methods for treating wounds with negative pressure, it must be assumed that jury adopted lower level of skill proposed by defendant, whose expert testified that level of ordinary skill in art would include &ldquo;health care professionals, for example physicians or nurses,&rdquo; or &ldquo;a podiatrist or somebody else, who has additional training or knowledge about wound care,&rdquo; or &ldquo;engineers with experience operating or designing equipment used in conjunction with wound care.&rdquo;</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926086" href="#headnote_ref_pq2-dec_926086">[7]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Combining references </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0905" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0905">&#9658;115.0905</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's conclusion that there are significant differences between cited prior art references and asserted claims of patents in suit, which are directed to apparatus and methods for treating wounds with negative pressure, since there is substantial evidence that none of three cited references discloses use of negative pressure for wound healing, that two of three references do not relate to treatment of &ldquo;wounds&rdquo; as that term is used in claims, and that two of three references do not disclose use of seal capable of maintaining negative pressure on wounds; even if references disclosed all limitations of asserted claims, infringement defendant offered no evidence establishing reason to combine them, and plaintiff offered substantial evidence that person of ordinary skill in art had no reason to combine references to arrive at claimed invention, and in view of jury's conclusion that defendant failed to prove obviousness, it must be assumed that jury made factual finding, supported by substantial evidence, that there was no reason to combine prior art references.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926087" href="#headnote_ref_pq2-dec_926087">[8]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Secondary considerations generally </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0907" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0907">&#9658;115.0907</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Substantial evidence supports jury's finding of objective indicia of nonobviousness for inventions of patents in suit, which are directed to apparatus and methods for treating wounds with negative pressure, since infringement plaintiff presented evidence that leading experts in field were skeptical that &ldquo;counterintuitive&rdquo;
device and method could work, that, despite this initial skepticism, device produced unexpected and superior results and came to be widely praised and adopted over time, that effectiveness of device and such praise has made device commercial success with $1.4 billion in annual sales, and that device has been copied, and since defendant offered no rebuttal evidence, and its invalidity expert admitted that he did not consider objective indicia of nonobviousness in reaching his validity conclusions.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_926088" href="#headnote_ref_pq2-dec_926088">[9]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Combining references </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0905" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0905">&#9658;115.0905</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Secondary considerations generally </span> <a href="http://www.bloomberglaw.com/document/1721688195075/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0907" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0907">&#9658;115.0907</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_13" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_13" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court erred in granting judgment as matter of law that inventions of patents in suit, which are directed to apparatus and methods for treating wounds with negative pressure, are invalid for obviousness, since expert testimony regarding motivation to combine is not always required, but for technology at issue, common sense would not provide motivation to combine primary prior art references, since creation of claimed apparatus or method would require, at minimum, combining references that disclose treatment or healing of wounds with publications that disclose seal capable of maintaining negative pressure on wound, but record is devoid of any reason why person of ordinary skill in art would make such combination, since all doctors who created devices disclosed in prior art removed them from patients after wounds were drained but before healing with negative pressure began, which indicates that doctors were not using disclosed devices and methods to heal wounds with negative pressure, and that they did not believe that devices were capable of such healing, since there is significant evidence that cited references taught away from claimed inventions, since claims cannot be found obvious based on belief that they contained elements that were not new, and since evidence establishes nearly every indicia of nonobviousness, which weighs strongly against finding of obviousness; objective indicia serve particularly important role if there is battle of scientific experts regarding obviousness issue, since they provide unbiased indication regarding credibility of such evidence.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Western District of
Texas, W. Royal Furgeson, Jr., <span CLASS="page_no" data-cite="688 f 3d 1345" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1345" data-primary-citation="688 F3d 1342">[*1345]</span> J.

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>

Matthew D. Powers, Weil, Gotshal &amp; Manges LLP, of Redwood Shores, CA, argued
for plaintiff-appellant. With him on the brief were Elizabeth Stotland
Weiswasser, Peter Sandel, <span CLASS="page_no" data-cite="104 uspq 2d 1004" data-cite-type="ReporterOfDecisions" data-cite-pageno="1004" data-primary-citation="104 U.S.P.Q.2d 1001">[**1004]</span> Jennifer H. Wu, Danielle Rosenthal and Erin
Wiggins, of New York, NY. Of counsel was Andrew Swanson Brown.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Joseph R. Re, Knobbe, Martens, Olson &amp; Bear, LLP, of Irvine, CA, argued for
defendant-appellee. With him on the brief were James F. Lesniak, Shelia N.
Swaroop and Christy G. Lea. Of counsel on the brief was Mark J. Gorman,
Smith &amp; Nephew, Inc., of Cordova, TN.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before BRYSON, DYK and O'MALLEY, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
O'MALLEY, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed by Circuit Judge O'MALLEY. Circuit Judge DYK
concurs in the result.
<span CLASS="page_no" data-cite="688 f 3d 1346" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1346" data-primary-citation="688 F3d 1342">[*1346]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest University Health Sciences ("Wake Forest") appeals the
district court's grant of judgment as a matter of law ("JMOL") of invalidity
for obviousness. In granting Smith &amp; Nephew, Inc.'s ("S &amp; N") motion for
JMOL, the district court overturned the jury's determination that S &amp; N had
failed to prove that the asserted claims of the patents in suit were
obvious. We conclude that, on the basis of the jury's factual findings, S &amp;
N failed to establish by clear and convincing evidence that the claims were
obvious. Accordingly, we reverse and remand.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. Asserted Patents
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Kinetic Concepts, Inc., KCI Licensing, Inc., KCI USA, Inc., KCI Medical
Resources, KCI Manufacturing, and Medical Holdings Limited (collectively
"KCI") and Wake Forest brought suit against S &amp; N, alleging infringement of
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=U.S.%20Patent%20Nos.%207,216,651&amp;summary=yes#jcite">U.S. Patent Nos. 7,216,651</a> ('"<cite>651 patent</cite>") <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=and%205,645,081&amp;summary=yes#jcite">and 5,645,081</a> ('"<cite>081 patent</cite>").
Wake Forest is the owner of the asserted patents, and KCI are the exclusive
licensees of the patents. Both patents claim methods and apparatuses for
treating difficult-to-heal wounds by applying suction or negative pressure,
<i>e.g.</i>, '<cite>651 patent</cite> Abstract; '<cite>081 patent</cite> Abstract. Wake Forest and KCI
asserted that S &amp; N infringes apparatus claims 2 and 5 of the '<cite>081 patent</cite>
and induces infringement of method claims 42, 109, 116, and 121 of the '<cite>651
patent</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As described by the asserted patents, medical "treatment of open wounds
that are too large to spontaneously close" is difficult. '<cite>081 patent</cite> col. 1
ll.11-12; '<cite>651 patent</cite> col. 1 ll.29-30. "Wound closure requires that
epithelial and subcutaneous tissue migrate from the wound border toward the
wound."'<cite>081 patent</cite> col. 2 ll.49-50. To facilitate such migration, doctors
commonly use mechanical closures, such as sutures or staples. <i><cite>Id</cite>.</i> at col. 1
ll.24-25. Such mechanical closures create tension on the skin, which
encourages epithelial migration. <i><cite>Id</cite>.</i> at col. 1 ll.25-28. "While suturing and
stapling <span CLASS="page_no" data-cite="2012 bl 204409 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> of wounds is widely practiced, it has a major drawback: the tensile
force required to achieve closure with sutures or staples causes very high
localized stresses at the suture insertion points, resulting in the rupture
of the tissue at these points." <i><cite>Id</cite>.</i> at col. 1 ll.28-33. This rupturing
inhibits healing of the wound. <i><cite>Id</cite>.</i> at col. 1 ll.33-35. Additionally, it is
not feasible to suture some large open wounds. <i><cite>Id</cite>.</i> at col. 1 ll.28-33.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To address these shortcomings, the invention applies "negative pressure to
a wound over an area sufficient to promote migration of epithelial and
subcutaneous tissue toward the wound, with the negative pressure being
maintained for a time sufficient to facilitate closure of the wound." <i><cite>Id</cite>.</i> at
col. 2 ll.45-49; '<cite>651 patent</cite> col. 4 ll.18-23 ("[A] method of treating tissue
damage is provided which comprises applying a negative or reduced pressure
to a wound over an area sufficient to promote the migration of epithelial
and subcutaneous tissue toward the wound and for a time period sufficient to
facilitate closure of the wound."). Claim 2 of the '<cite>081 patent</cite> and claim 42
of the '<cite>651 patent</cite> are illustrative:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      2. An apparatus for facilitating the healing of wounds,
    comprising:
<span CLASS="page_no" data-cite="688 f 3d 1347" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1347" data-primary-citation="688 F3d 1342">[*1347]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      vacuum means for creating a negative pressure between about 0.1
    and 0.99 atmospheres on the area of skin including and surrounding
    the wound;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      sealing means operatively associated with said vacuum means for
    maintaining said negative pressure on said wound by contacting the
    skin surrounding said wound; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      open-cell polymer for positioning at the wound within the sealing
    means for preventing the overgrowth of tissue in the wound.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<cite>'081 patent</cite> col. 9 ll.50-65.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      42. A method of treating a wound comprising the steps of:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      i. providing a vacuum source capable of providing at least 0.11
    atm of reduced pressure;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      ii. locating a flexible adhesive cover over the wound, said cover
    having a suction port;
<span CLASS="page_no" data-cite="104 uspq 2d 1005" data-cite-type="ReporterOfDecisions" data-cite-pageno="1005" data-primary-citation="104 U.S.P.Q.2d 1001">[**1005]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      iii. locating a porous material comprising a synthetic polymer
    under said cover at the wound;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      iv. adhesively sealing and adhering the periphery of said cover to
    tissue surrounding the wound to form a continuous seal;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      v. operably connecting said suction port with said vacuum system
    for producing said reduced pressure;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      vi. interposing a fluid trap between said suction port and said
    vacuum source; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      vii. maintaining reduced pressure of at least 0.11 atm at the
    wound until the wound had progressed toward a selected stage of
    healing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<cite>'651 patent</cite> col. 25 ll.31-48.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Figure 1 of the '<cite>651 patent</cite> discloses the key components of the claimed
apparatus:
<span CLASS="page_no" data-cite="688 f 3d 1348" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1348" data-primary-citation="688 F3d 1342">[*1348]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1I3E9Q003?documentName=72603_a">EXHIBIT</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As depicted in this figure, the claimed apparatus includes: (1) a vacuum
pump (30); (2) tubing (12); (3) an open-celled foam wound screen (10); and
(4) an adhesive seal (18). '<cite>651 patent</cite> col. 6 ll.31-61; <i>see also</i> '<cite>081 patent</cite>
col. 2 ll.30-35 ("FIG. 1 shows a cross-sectional view of a negative pressure
device comprising a open-cell polymer screen, a flexible hose connecting the
foam section to a suction pump, and a flexible polymer sheet overlying the
foam-hose assembly to provide the necessary seal."). To utilize the
apparatus, "[f]irst, the open cell foam is cut to fit the shape of the wound
<span CLASS="page_no" data-cite="2012 bl 204409 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> and placed inside the wound. Then the adhesive seal is placed over the foam
that is inside the wound." <i>Kinetic Concepts, Inc. v. Blue Sky Med. Grp.,</i>
<i>Inc.</i>, No. <cite>08-cv-102</cite>, <cite>slip op. at 2</cite> (W.D.Tex. Oct. 10, 2010) (order granting
defendant's motion for judgment as a matter of law of invalidity for
obviousness) (ECF No. 605) ("<i>JMOL Order</i>"). Once the seal is in place, "[o]ne
end of the tubing is placed through the seal into the foam and the other end
is attached to the vacuum pump. The vacuum pump is turned on and, because of
the tight seal around the wound, the edges of the wound immediately begin to
move together." <i><cite>Id</cite>.<span CLASS="page_no" data-cite="104 uspq 2d 1006" data-cite-type="ReporterOfDecisions" data-cite-pageno="1006" data-primary-citation="104 U.S.P.Q.2d 1001">[**1006]</span> </i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the present litigation, S &amp; N asserted prior art that generally falls
into three primary categories: (1) the Bagautdinov references; (2) the
Zamierowski reference; and (3) the Chariker-Jeter references. On appeal,
there is no dispute that these references are all prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Bagautdinov References
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Bagautdinov references consist of two articles written by Dr.
Bagautdinov.
<span CLASS="page_no" data-cite="688 f 3d 1349" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1349" data-primary-citation="688 F3d 1342">[*1349]</span> 
The first reference ("Bagautdinov I") was published in 1986. Joint Appendix
("J.A.") 10001-03. It discusses "a method for vacuum treatment of primary
and secondary purulent wounds." J.A. 10002. The reference describes the
method as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      After surgical treatment of the purulent wound and hemostasis, a
    drain of polyurethane foam adapted in shape and size is placed on
    the surface (or in the cavity). The surrounding skin is smeared with
    sterile vaseline, antiseptic or inert salve on an oil base and
    covered with a polyethylene film. . . . Regardless of the method of
    sealing, a tube is hermetically installed onto the foam through a
    hole in the polyethylene made beforehand. The latter is connected to
    the vacuum pump through a collection vessel. At a vacuum of 10 to 60
    mmHg the film clenches the wound strictly along its skin boundaries
    with uniform vacuum treatment of the walls only on the side of the
    cavity and elimination of exudate because of the porous structure of
    the drain. The duration of the treatment sessions depends on the
    degree of vacuum and ranges from 30 minutes to 2 hours, whereupon
    the polyethylene is removed and a gauze bandage emplaced. The
    sessions are conducted daily until the wound is clean. On average
    this procedure takes 3 to 4 days.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><cite>Id</cite>.</i> Bagautdinov I notes that use of this method "inevitably obtain[s]
acceleration of the healing periods and rehabilitation of the patients."
J.A. 10003. The second reference ("Bagautdinov II") was also published in
1986. J.A. 10026-27. Bagautdinov II describes application of a method
similar to that described in Bagautdinov I to 170 patients. J.A. 10026. The
method employed requires that,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [i]mmediately after surgical treatment of the infected area in the
    commonly accepted manner or using a Scalpel-1 laser, a drain made
    from polyurethane foam is placed in the wound. For sorption
    treatment, it is first filled with activated charcoal powder. The
    wound is sealed with polyethylene film in one of several ways,
    depending on the localization of the purulent focus. Vacuum
    aspiration is conducted through an aspiration tube using a constant
    suction pump. Thus, <span CLASS="page_no" data-cite="2012 bl 204409 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> the polyethylene film "clenches" the wound
    strictly along its edges, and the sorbent makes secure contact with
    the walls. The porous structure of the drain allows for removal of
    exudate and vacuumization of the wound only from the cavity side.
    The session lasts 1-2 hours with negative pressure of 10-40 mmHg,
    after which the isolation is removed. The drain is changed 1-2 times
    daily. Vacuum treatment was continued for 3-4 days.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 10026-27. As a result of this method, "[o]n average, the wound became
clean by day 4-5, with the appearance of granulated tissue. . . . The
average duration of inpatient treatment was 11.8 bed days, compared to 17.2
in the control group; 61.7% of the patients were released with healed wounds
and did not require outpatient treatment." J.A. 10027.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Zamierowski Reference
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Zamierowski reference is a Patent Cooperation Treaty Application filed
on April 3, 1990. J.A. 10057. The reference describes a "fluidic connection
system . . . for draining liquids from and introducing liquids to patients."
J.A. 10059. As described by the reference, the system, which amounts to a
wound dressing, consists of:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [A] semipermeable membrane including a pair of panels each having
    a perimeter
<span CLASS="page_no" data-cite="688 f 3d 1350" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1350" data-primary-citation="688 F3d 1342">[*1350]</span> 
    and an edge strip. The membrane is formed by connecting the panel
    edge strips together to form a seam extending transversely across
    the membrane. The panels and the membrane include inner and outer
    surfaces. A tube opening extends through the seam between the panel
    edge strips and between the membrane inner and outer surfaces. The
    membrane inner surface is coated with an adhesive for attachment to
    the skin of a patient. A tube or sheath includes a proximate end
    extending through the tube opening and a distal end positioned in
    spaced relation from the membrane outer surface. . . . A passage
    extend[s] through the sheath between its ends. An inner conduit can
    be placed in the sheath passage and can include a connection seal
    assembly for forming <span CLASS="page_no" data-cite="104 uspq 2d 1007" data-cite-type="ReporterOfDecisions" data-cite-pageno="1007" data-primary-citation="104 U.S.P.Q.2d 1001">[**1007]</span> a fluid-tight seal with the sheath. . . . When
    the fluidic connection system is used as a wound dressing, an
    intermediate layer of material can be applied between the wound and
    the cover membrane inner surface. Furthermore, the fluidic
    connection system of the present invention can be used to secure a
    percutaneous drainage tube within a patient, e.g. by inserting the
    percutanious tube through the sheath passage. . . . The cover
    membrane can be releasably, adhesively fastened to the skin around a
    periphery thereof. A tube fluidically communicates with the wound
    through an opening in the membrane. Fluids from a draining wound can
    be evacuated through the tube and liquid medication and irrigation
    can be introduced through the tube to the wound site. The fluid
    evacuation and introduction steps of the method can each be
    accomplished both actively and passively. . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 10061-63. The reference indicates that this wound dressing "promotes
healing." J.A. 10063.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. Chariker-Jeter References
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Chariker-Jeter references consist of two published articles
("Chariker-Jeter I" and "Chariker-Jeter II," respectively), J.A. 10044-47;
J.A. 10050-56, and Dr. Chariker'<span CLASS="page_no" data-cite="2012 bl 204409 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> s 1989 public use of the system described in
the articles on Gary Aderholt ("Chariker-Jeter public use"). Both
Chariker-Jeter I and Chariker-Jeter II describe the same "closed wound
drainage system." J.A. 10052. As described in Chariker-Jeter II, the
drainage system is created by:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. Irrigat[ing] the wound bed thoroughly with normal saline using
    a 30ml syringe with a 19-gauge needle.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      2. Moisten one 2X2 gauze square with normal saline. Open
    completely and lay across the wound bed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      3. Place Jackson-Pratt drain in wound bed. Shorten the fenestrated
    drain as necessary so that the flat drain is confined to the wound
    bed. The drain is never placed in the fistula<a HREF="#fn200" name="fnref_fn200">[fn2]</a> tract. In the
    case of fistula drainage at skin level, the fenestrated portion of
    the drain is simply centered over the cutaneous opening. It may be
    helpful to encircle the cutaneous wound with a pectin-based skin
    barrier in order to create a "trough" in which to situate the
    fenestrated drain.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      4. Saturate 4X4 gauze squares with normal saline. Open and fluff
    into wound to completely cover the drain and fill the defect to skin
    level. In the case of a cutaneous fistula, only enough moist
<span CLASS="page_no" data-cite="688 f 3d 1351" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1351" data-primary-citation="688 F3d 1342">[*1351]</span> 
    gauze to cover the flat fenestrated drain is required
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      5. Apply skin sealant (Bard Barrier Film, Skin-Prep, etc.) to all
    skin that will be covered by the film dressing. Allow to dry until
    slick.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      6. Cut the film dressing or select a size to allow at least linch
    of intact skin beyond the wound edges. Place the film dressing over
    the packed wound. Carefully crimp the adhesive film dressing around
    the Jackson-Pratt tube to seal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      7. "Caulk" the tube exit site with a small amount of Stomahesive
    Paste where the film dressing is crimped around the tube. This
    ensures air-tight closure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      8. Reinforce this site with waterproof "pink tape" as illustrated.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      9. Turn your attention now to the connection of the Jackson-Pratt
    to continuous suction. (Do not attempt to use the bulb of the
    Jackson-Pratt system.) With some brands of canister and tubing, all
    that is necessary is to cut the funnel end off the tubing and the
    small J-P tubing will fit snugly into the larger lumen tube. The
    junction should be taped securely with pink tape. Otherwise you may
    use small "Christmas tree" connector or cannibalize IV tubing to get
    a small plastic adapter to connect the tubing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      10. Turn on continuous suction to the upper range of the low
    setting (approximately 60 to 80 mmHg) and observe the wound site.
    The dressing should contract noticeably. If it does not, the system
    is not closed and wound drainage will not be efficiently removed.
    When this occurs, fistula drain age will accumulate, causing skin
    damage and leakage outside of the dressing. Another indication that
    you have not obtained a closed suction system is a whistling sound
    indicating that the dressing is not air-tight.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 10052 (footnote added). Chariker-Jeter II explains that "[o]ur clinical
observations suggest <span CLASS="page_no" data-cite="104 uspq 2d 1008" data-cite-type="ReporterOfDecisions" data-cite-pageno="1008" data-primary-citation="104 U.S.P.Q.2d 1001">[**1008]</span> that fistula effluent does inhibit wound healing. . . .
By minimizing the inflammatory response [associated with the presence of
effluent], fibroplasia is reduced. This, we believe, encourages rapid wound
contraction <span CLASS="page_no" data-cite="2012 bl 204409 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> and re-epithelialization." J.A. 10055.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, with respect to the Chariker-Jeter public use, Dr. Chariker
testified that he treated Mr. Aderholt in 1989 with his closed suction wound
drainage system. "[Mr. Aderholt] was injured with a log chain that flew off
another truck into his truck, entered his chest, his abdomen, ruptured his
lung, his [diaphragm], his pancreas, his spleen, his stomach." J.A.
22032:8-11. With the aid of pictures of Mr. Aderholt's treatment, Dr.
Chariker stated that his treatment was an example of the drainage system
facilitating the healing of a wound on a patient without a fistula. J.A.
22035:6-38:11.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III. Prior Litigation
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 2003, Wake Forest and KCI sued Blue Sky Medical Group, Inc., ("Blue
Sky") et al., alleging that its gauze based negative pressure wound therapy
products infringed <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=U.S.%20Patent%20No.%205,636,643&amp;summary=yes#jcite">U.S. Patent No. 5,636,643</a><a HREF="#fn300" name="fnref_fn300">[fn3]</a> ('"<cite>643 patent</cite>") and the
'<cite>081 patent</cite>. At trial, a jury found the patents were not infringed, not
invalid, and not unenforceable. At the close of trial, defendants filed a
motion for judgment as a matter of law, alleging that
<span CLASS="page_no" data-cite="688 f 3d 1352" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1352" data-primary-citation="688 F3d 1342">[*1352]</span> 
the asserted claims of the '<cite>643</cite> and '<cite>081 patents</cite> were invalid as obvious
under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. The district court denied that motion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, this court affirmed the jury's finding that invalidity was not
established and that the asserted claims were not infringed. <i>Blue Sky</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d at 1025-26</a>. In reaching that conclusion, however, we determined
that the district court committed harmless error by failing to construe the
term "wound." <i></i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20F.3d%20at%201025-26&amp;summary=yes#jcite">Id. at 1019</a>. While we did not provide a definitive
construction of "wound," we concluded that construing "'wound' to include
fistulae and 'pus pockets' would [] expand the scope of the claims far
beyond anything described in the specification." <i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20F.3d%20at%201025-26&amp;summary=yes#jcite">Id</a>.</i> Significantly, for the
present appeal, we also concluded that "wound," "as used in the asserted
patents, does not cover the fistulae described in the Chariker-Jeter
publications. . . ." <i></i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20F.3d%20at%201025-26&amp;summary=yes#jcite">Id. at 1018</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV. Present litigation
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During the appeal in the prior litigation, S &amp; N acquired Blue Sky. In
December 2008, S &amp; N announced it was launching a new foam-based negative
pressure wound treatment product. Responding to this announcement, Wake
Forest and KCI filed this suit, asserting that S &amp; N's Renasys product
infringed the asserted patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After conducting a <i>Markman</i> hearing, the district court construed various
terms recited in the claims. For this appeal, the court's construction of
only the term "wound" is relevant; it construed this term to mean: "tissue
damage to the surface of the body, including the epithelial and subcutaneous
layers, and excluding fistulae and pus pockets." <i>Kinetic Concepts, Inc. v.</i>
<i>Blue Sky Med. Grp., Inc.</i>, <cite>No. 08-cv-102</cite>, <cite>slip op. at 8</cite> (W.D.Tex. Nov. 12,
2009) (claim construction order) (ECF No. 280) ("<i>Claim Construction Order");</i>
<i>see also JMOL Order</i> at 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Before the case was given to the jury for determination, the parties
disagreed about the form and content of the jury instructions. Wake Forest
and KCI had demanded a trial by jury. In response, S &amp; N moved the district
court to strike the jury demand with respect to questions of law, including
the ultimate question of obviousness. Def.'s Mot. to Strike Pls.' Jury
Demand on Questions <span CLASS="page_no" data-cite="2012 bl 204409 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> of Law at 5-9, <i>Kinetic Concepts, Inc. v. Blue Sky Med.</i>
<i>Grp., Inc.</i>, OS-cv-102 (W.D.Tex. Jan. 21, 2010) (ECF No. 397) ("<i>Motion to</i>
<i>Strike</i> "). Prior to ruling on the merits of the motion to strike, the
district court conducted an on-the-record pre-trial hearing. During the
hearing, S &amp; N made clear that it wanted the jury to make findings with
respect to the factors under <i>Graham v. John Deere Co. of Kansas City</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966), and reserve the ultimate
question of obviousness for the judge. Pre-Trial Conference Tr. at 16-22,
<i>Kinetic Concepts, Inc. v. Blue Sky Med. Grp., Inc.</i>, No. 08-cv-102 (W.D.Tex.
Jan. 25, 2010) ("Pre-<i>Trial Conference Transcript</i>"). To facilitate this
division of responsibility, S &amp; N proposed a special interrogatory verdict
form:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [T]he way it's done and the way the models show . . . is the jury
    make[s] findings under <i>Graham v. John Deere.</i> If the jury is actually
    asked what is the level of skill in the art, that's one of the
    <i>Graham</i> findings. What is the scope and content of the prior art. . .
    . [W]e proposed and gave to KCI a two-page set of questions where we
    are specifically asking the jury to make findings as to whether or
    not the prior art contains a particular suggestion.
<span CLASS="page_no" data-cite="688 f 3d 1353" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1353" data-primary-citation="688 F3d 1342">[*1353]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><cite>Id. at 16</cite>. Under this proposal, the trial judge would resolve the ultimate
question of obviousness on the basis of the jury's factual findings as
exemplified in their answers to the interrogatories.
<span CLASS="page_no" data-cite="104 uspq 2d 1009" data-cite-type="ReporterOfDecisions" data-cite-pageno="1009" data-primary-citation="104 U.S.P.Q.2d 1001">[**1009]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest and KCI expressed the belief that this proposal was "one of
the worst ideas of all time" because it would make the process so
complicated that the jury could not get it right, thereby "taking away from
the jury the power they have been given by the constitution." <i></i><cite>Id. at 23</cite>.
Highlighting their concern with S &amp; N's proposed verdict form, Wake Forest
and KCI explained that: "It's not two pages, but actually five pages of
questions. Two pages that look like this of detailed questions about whether
the prior art discloses teeny tiny aspects of the patent, and two questions
that call for a narrative answer from the jury." <i></i><cite>Id. at 26</cite>. Responding to
this criticism, the trial judge indicated that he was "very reluctant . . .
to give juries questions requiring narrative answers." <i></i><cite>Id. at 27</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The trial judge summarized the parties' arguments as both saying
essentially the same thing: "[N]o matter how I present this to the jury I
have to make a separate determination as to obviousness. Even if I were to
submit this to the jury in a broad form submission &mdash; just is it obvious &mdash;
regardless of what the jury said, my analysis would have to require that I
do my own look at the matter from a legal point of view. . . ." <i></i><cite>Id. at 30</cite>.
The trial judge concluded the discussion of the <i>Motion to Strike</i> by
indicating that he would read the materials presented by the parties and
consider using special interrogatories. He cautioned, however, that, "while
I'm open to a special interrogatory presentation, I'm not open to a special
interrogatory presentation that goes on and on and on." <i></i><cite>Id. at 30-31</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Four days after conducting the pre-trial hearing, the district court
denied S &amp; N's request that it not submit the ultimate question of
obviousness to the jury. <i>Kinetic Concepts, Inc. v. Blue Sky Med. Grp., Inc.</i>,
<cite>No. 08-cv-102</cite>, <cite>slip op. at 4-5</cite> (<span CLASS="page_no" data-cite="2012 bl 204409 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> W.D.Tex. Jan. 29, 2010) (order granting in
part and denying in part defendant's motion to strike plaintiffs jury demand
on questions of law) (ECF No. 407). It concluded that "[t]he jury
instructions shall explain the underlying factual issues that the jury must
resolve as well as the legal standard for determining obviousness.
Additionally, the jury verdict form shall specifically ask the jury to
determine the underlying <i>Graham</i> factors, and make a final determination of
obviousness that the court will consider as advisory." <i></i><cite>Id. at 5</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In accordance with this ruling, the parties began developing proposed
joint jury instructions and a special verdict form. At the close of the
presentation of evidence, the parties were still developing the instructions
and the verdict form. Jury Trial Tr. Day 10 at 2806, <i>Kinetic Concepts, Inc.</i>
<i>v. Blue Sky Med. Grp., Inc.</i>, <cite>No. 08-cv-102</cite> (W.D.Tex. Feb. 23, 2010) ("<i>Day 10</i>
<i>Trial Transcript</i>"). Because the jury instructions and verdict form were not
complete and there was some disagreement over the exact form the documents
should take, the district court held a charge conference to resolve any
remaining disputes, and finalize the instructions and the verdict form. At
this stage in the proceeding, the obviousness verdict form proffered by S &amp;
N was eighteen pages in length, and Wake Forest and KCFs was slightly more
than seven pages in length. <i></i><cite>Id. at 2969-70</cite>. Each of the proposed verdict
forms contained specific questions addressing the differences, if any,
between the asserted claims and the three categories of prior art discussed
above. After reviewing the proposals,
<span CLASS="page_no" data-cite="688 f 3d 1354" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1354" data-primary-citation="688 F3d 1342">[*1354]</span> 
the judge stated, "I really can't give them this. . . . I may have to try to
figure out something else to give them, but this won't work." <i></i><cite>Id. at 2985</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The judge explained his belief that, if the verdict form only posed the
ultimate question to the jury, the court would be left with little guidance
regarding the factual predicate for the jury's resolution of that issue. <i></i><cite>Id.
at 2990-91</cite>. The district court, therefore, expressed its preference to ask
the jury specific questions about the various <i>Graham</i> factors, in addition to
asking the jury its view on the ultimate conclusion of obviousness. <i></i><cite>Id. at
2992-94</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After discussing the various options with the parties, the judge decided
that the best option was to allow the parties to draft a 300-word
description of what the parties asserted were the differences between the
three main categories of prior art and each of the asserted claims. These
"jury contentions" would be included in the jury instructions. Then the jury
verdict form would ask what differences, if any, the jury found between the
given claim and the three main categories of prior art, providing space for
the jury to list the differences in a narrative. <i></i><cite>Id. at 2997-3006</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With these guidelines, the judge dismissed the parties to finish drafting
the jury instructions and verdict form, explaining that that they would meet
that evening when the instructions and verdict form were complete. <i></i><cite>Id. at
3003-04</cite>. The judge advised the parties, however, that "if you've got any
better idea on obviousness <span CLASS="page_no" data-cite="2012 bl 204409 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> that you can agree to, I'll be glad to do it, but
what you've come up with so far we're not going to do. And so, if you can't
come up with anything, then you just have to do it the way I said, which I
think is not optimal." <i></i><cite>Id. at 3062</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  When the parties met that night with the judge, a court reporter was not
present, so there is no record of the discussion. It is clear from looking
at the jury instructions and the verdict form as presented to the jury,
however, that the parties and the judge agreed to use a <span CLASS="page_no" data-cite="104 uspq 2d 1010" data-cite-type="ReporterOfDecisions" data-cite-pageno="1010" data-primary-citation="104 U.S.P.Q.2d 1001">[**1010]</span> different format
than suggested by the judge at the close of the charge conference. Although
the jury instructions contain a discussion of the parties' contentions
regarding the differences between the prior art and the claims, Jury Trial
Tr. Day 11 at 3098-3102, <i>Kinetic Concepts, Inc. v. Bins Sky Med. Grp., Inc.</i>,
<cite>No. 08-cv-102</cite> (W.D.Tex. Feb. 24, 2010) ("<i>Day 11 Trial Transcript</i>"), the
verdict form did not allow the jury to provide a narrative about which
differences they found to exist, nor did it pose questions regarding all of
the <i>Graham</i> factors. J.A. 65-89. Instead, in questions 5(A)-(C), the jury was
asked whether several enumerated differences between the prior art and the
asserted claims were the only differences that existed. The jury was simply
instructed to answer yes or no. In addition, in question 5(D), the verdict
form contained a chart that allowed the jury to indicate whether they found
certain objective indicia of nonobviousness to be present with respect to
each of the asserted claims. J.A. 70. Finally, in question 6, the verdict
form asked the jury to decide whether S &amp; N had proven that the asserted
claims were obvious. J.A. 71.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury determined that the claims and the prior art exhibited
differences in addition to those listed, J.A. 64-69, that most of the
objective considerations favoring nonobviousness were present with respect
to each claim, that infringement was proven, and that obviousness was not
established. J.A. 62-63; 71. After the verdict was read to the parties, the
district court indicated that the parties should prepare post-trial motions
if they wished to challenge the jury's verdict. Jury Verdict Tr.
<span CLASS="page_no" data-cite="688 f 3d 1355" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1355" data-primary-citation="688 F3d 1342">[*1355]</span> 
at 12-13, <i>Kinetic Concepts, Inc. v. Blue Sky Med. Grp., Inc.</i>, <cite>No. 08-cv-102</cite>
(W.D.Tex. Mar. 10, 2010) ("<i>Jury Verdict Transcript</i>").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pursuant to Rule <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3U003?jcsearch=Fed.R.Civ.P.%2050(b)&amp;summary=yes#jcite">50</a>(b) of the Federal Rules of Civil Procedure, S &amp; N
moved for JMOL, arguing that all of the asserted claims of the '<cite>081</cite> and '<cite>651
patents</cite> were obvious. In its motion, S &amp; N asserted that substantial
evidence did not support the jury's explicit findings that (1) additional
differences between the prior art and the asserted claims existed, and (2)
that multiple objective indicia of nonobviousness were present.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Responding to S &amp; N's motion, Wake Forest and KCI argued that, in addition
to the explicit jury findings, the jury's implicit findings necessary to
determine the ultimate question of obviousness should be presumed to have
been found in Wake Forest and KCI's favor. Furthermore, these findings, both
explicit and implicit, should not be disturbed by the trial court unless
they are not supported by substantial evidence. In light of this standard,
Wake Forest <span CLASS="page_no" data-cite="2012 bl 204409 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> and KCI asserted that substantial evidence supported the jury's
factual determinations: (1) that additional differences existed between the
prior art and the asserted claims; (2) that objective indicia of
nonobviousness were present; and (3) that teaching away was demonstrated
with respect to the Bagautdinov and Chariker-Jeter references. On the basis
of these findings, Wake Forest and KCI asserted that S &amp; N's motion should
be denied because it failed to establish that the asserted claims were
obvious as a matter of law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Replying to Wake Forest and KCI, S &amp; N highlighted that the jury's verdict
of nonobviousness was advisory only. Accordingly, it argued that there were
no implicit factual findings in support of the advisory verdict on
nonobviousness to which the court should defer. Instead, S &amp; N asserted that
"as the ultimate decision-maker on obviousness, th[e] [district] [c]ourt has
the responsibility to make its own findings, based upon the current record,
necessary to support its own legal conclusion regarding obviousness." Def.'s
Reply in Supp. of its Renewed Mot. for J. as a Matter of Law of Invalidity
for Obviousness and Mot. for New Trial at 1, <i>Kinetic Concepts, Inc. v. Blue</i>
<i>Sky Med. Grp., Inc.</i>, <cite>No. 08-cv-102</cite> (W.D.Tex. May 12, 2010) (ECF No. 548).
Based upon this understanding of how the jury's verdict should be reviewed
by the district court, S &amp; N argued that the asserted claims were obvious as
a matter of law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prior to ruling on the merits of S &amp; N's motion, the court conducted a
hearing. S &amp; N began by arguing that, because the jury's verdict on the
ultimate question of obviousness was advisory, it is inappropriate to "just
assume every finding of fact in favor of the jury's nonobviousness verdict.
Post-Trial Hr'g Tr. at 133, <i>Kinetic Concepts, Inc. v. Blue Sky Med. Grp.,</i>
<i>Inc.</i>, <cite>No. 08-cv-102</cite> (W.D.Tex. May 17, 2010) ("Post-<i>Trial Hearing</i>
<i>Transcript</i>"). Indeed, S &amp; N argued that implied findings of fact only arose
with respect to questions 5(A)-(C), regarding additional differences, and
5(D), regarding the existence of objective indicia of nonobviousness. <i></i><cite>Id. at
133-34</cite>, 36. "It is not simply enough to say the jury found obviousness,
implied every finding of fact in our favor, which is what KCI is arguing,
and therefore the verdict should be upheld. Not true. They are only entitled
to implied findings to the extent they are encompassed by the Verdict
Question 5, not 6." <i></i><cite>Id. at 136</cite>. S &amp; N argued that substantial evidence did
not support the jury's factual finding that additional
<span CLASS="page_no" data-cite="688 f 3d 1356" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1356" data-primary-citation="688 F3d 1342">[*1356]</span> 
patentably significant differences existed between the prior art and the
asserted claims and that objective indicia of nonobviousness were present.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest and KCI, on the other hand, argued that the jury's verdict on
the ultimate question of obviousness is always advisory <span CLASS="page_no" data-cite="104 uspq 2d 1011" data-cite-type="ReporterOfDecisions" data-cite-pageno="1011" data-primary-citation="104 U.S.P.Q.2d 1001">[**1011]</span> because, as a
question of law, it must be determined by the court. <i>See </i><cite>id. at 153</cite>.
Nonetheless, "the case law is absolutely clear that . . . [w]hen the jury
finds that [the claims] are not obvious, you have to assume that they find
the right underlying facts, and then the test is substantial evidence" for
the underlying factual findings. <i></i><cite>Id. at 155</cite>. Under this standard, Wake
Forest <span CLASS="page_no" data-cite="2012 bl 204409 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> and KCI argued that substantial evidence supported the jury's
explicit and implicit factual findings, and that S &amp; N's motion should have
been denied.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Ultimately, the district court indicated that it would "review[] the
jury's conclusions on obviousness, a question of law, without deference, and
the underlying findings of fact, whether explicit or implicit within the
verdict, for substantial evidence." <i>JMOL Order</i> at 8. After thoroughly
summarizing the relevant prior art, the district court concluded that,
contrary to the jury's explicit findings, "the differences between the
claimed invention and the prior art, if any, are minimal." <i></i><cite>Id. at 18</cite>.
Indeed, the district court concluded that the differences were so minor that
"such minimal variations would have been apparent to one having ordinary
skill in the art. . . ." <i></i><cite>Id. at 34</cite>. The court concluded, therefore, that
"the evidence is clear and convincing that there is no legally sufficient
basis on the record to conclude that all asserted claims of the patents in
suit were not obvious." <i><cite>Id</cite>.</i> The fact that the jury also found that several
objective indicia of nonobviousness were present did not alter the district
court's conclusion because, it said, "the Court is not convinced that they
overcome the strong case of obviousness established by the teaching in the
prior art." <i></i><cite>Id. at 35</cite>. Accordingly, the court granted S &amp; N's motion and
entered judgment in its favor. <i></i><cite>Id. at 37</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest timely appealed.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> We have jurisdiction pursuant to
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review a district court's grant of JMOL de novo, applying the law from
the regional circuit, the Fifth Circuit in this case. <i>Harris Corp. v.</i>
<i>Ericsson Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X12L8QM003?jcsearch=417%20f%203d%201241&amp;summary=yes#jcite">417 F.3d 1241</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X12L8QM003?jcsearch=417%20f%203d%201241&amp;summary=yes#jcite">1248</a> (Fed.Cir.2005). In the Fifth Circuit,
JMOL may be granted by the trial court only if "the facts and inferences
point so strongly and overwhelmingly in favor of one party that the Court
believes that reasonable men could not arrive at a contrary verdict. . . .
On the other hand, if there is substantial evidence opposed to the [grant of
JMOL] . . . [it] should be denied." <i>Broussard v. State Farm Fire &amp; Cas. Co.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18NPFC003?jcsearch=523%20f%203d%20618&amp;summary=yes#jcite">523 F.3d 618</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18NPFC003?jcsearch=523%20f%203d%20618&amp;summary=yes#jcite">624</a> (5th Cir.2008) (quoting <i>Brown v. Bryan (My.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3IS90?jcsearch=219%20f%203d%20450&amp;summary=yes#jcite">219 F.3d 450</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3IS90?jcsearch=219%20f%203d%20450&amp;summary=yes#jcite">456</a> (5th Cir.2000)). When evaluating the district court's grant of JMOL,
consideration is given to "all of the evidence, drawing all reasonable
inferences and resolving all credibility determinations in the light most
favorable to the non-moving party." <i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18NPFC003?jcsearch=523%20F.3d%20618&amp;summary=yes#jcite">Id</a>.</i> (quoting <i>Brown</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3IS90?jcsearch=219%20f%203d%20450&amp;summary=yes#jcite">219 F.3d at 456</a>).
Because obviousness is a mixed question of law and fact, "[w]e first presume
that the jury resolved the underlying factual disputes in favor of the
verdict[] and leave those presumed findings
<span CLASS="page_no" data-cite="688 f 3d 1357" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1357" data-primary-citation="688 F3d 1342">[*1357]</span> 
undisturbed if they are supported by substantial evidence. Then we examine
the [ultimate] legal conclusion [of obviousness] de novo to see whether it
is correct in light of the presumed jury fact findings." <i>Jurgens v. McKasy</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31U2G?jcsearch=927%20f%202d%201552&amp;summary=yes#jcite">927 F.2d 1552</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31U2G?jcsearch=927%20f%202d%201552&amp;summary=yes#jcite">1557</a> (Fed. Cir.1991) (internal citations omitted); <i>see also</i>
<i>Bos. Scientific Scimed, Inc. v. Cordis Corp.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1ADS48003?jcsearch=554%20f%203d%20982&amp;summary=yes#jcite">554 F.3d 982</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1ADS48003?jcsearch=554%20f%203d%20982&amp;summary=yes#jcite">990</a>
(Fed.Cir.2009) ("When we consider that, even in light of a jury's findings
of fact, the references demonstrate an invention to have been obvious, we
may reverse its obviousness determination." (citing <i>Richardson-Vicks, Inc.</i>
<i>v. Upjohn Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36F9U?jcsearch=122%20f%203d%201476&amp;summary=yes#jcite">122 F.3d 1476</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36F9U?jcsearch=122%20f%203d%201476&amp;summary=yes#jcite">1479</a> (Fed.Cir.1997))).
<span CLASS="page_no" data-cite="2012 bl 204409 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the face of what amounts to well settled law, S &amp; N argues that,
because the jury's verdict in this case was "advisory," "no factual findings
implied within the advisory verdict are binding. . . ." Appellee's Br. at
39. S &amp; N asserts, therefore, that we should review only the jury's explicit
factual findings with respect to questions 5(A)-(D) for substantial
evidence. Because the jury's advisory verdict on the ultimate question of
obviousness gave rise to no implied factual findings, S &amp; N contends the
district court was free to make its own findings of fact with respect to all
issues not submitted to the jury. <i></i><cite>Id. at 39-40</cite>. According to S &amp; N, we
should review these factual findings for clear error. Finally, S &amp; N argues
that the district court's ultimate conclusion regarding obviousness should
be reviewed de novo in light of the factual findings we find to be supported
by the evidence. We disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although S &amp; N is correct that the district court repeatedly referred to
the jury in this case as "advisory," S &amp; N is wrong about the implications
use of that term carries. We first address the ways in which the phrase
"advisory jury" is used by trial courts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The term is sometimes used to refer to Rule 39(c)(1) juries. Fed.R.Civ.P.
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">39</a>(c)(1) ("In an action not triable of right by a jury, the court, on motion
or on its own: may try any issue with an advisory jury. . . ."). Under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">Rule
39(c)(1)</a>, when an "advisory jury" is used, no jury findings &mdash; either
explicit or implicit <span CLASS="page_no" data-cite="104 uspq 2d 1012" data-cite-type="ReporterOfDecisions" data-cite-pageno="1012" data-primary-citation="104 U.S.P.Q.2d 1001">[**1012]</span> &mdash; are binding on the trial court and the court is
obligated to make independent findings of fact and conclusions of law on the
issue presented to the jury. S &amp; N first claims that the district court
submitted the matter to the jury under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">Rule 39(c)(1)</a> and that accordingly,
neither the trial court nor we are bound by the jury's factual findings. We
disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926080" href="#headnote_pq2-dec_926080">[1]</a> We do not believe that the district court intended to invoke <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">Rule 39(c)(1)</a>
when it referred to an "advisory jury." First, a Rule 39(c)(1) advisory jury
is available only in an action not triable by right to a jury. <i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">Id</a>.</i> But,
patent infringement actions must be tried to a jury if demanded by a party.
<i>Markman v. Westview Instruments, Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5CCQ2?jcsearch=517%20us%20370&amp;summary=yes#jcite">517 U.S. 370</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5CCQ2?jcsearch=517%20us%20370&amp;summary=yes#jcite">377</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=116%20supreme%20court%201384&amp;summary=yes#jcite">116 S.Ct. 1384</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5CCQ2?jcsearch=134%20l%20ed%202d%20577&amp;summary=yes#jcite">134 L.Ed.2d 577</a> (1996). Second, S &amp; N did not ask and the district court did
not make special findings that Rule 52 requires in all actions tried "with
an advisory jury." Fed.R.Civ.P. <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L42003?jcsearch=Fed.%20R.%20Civ.%20P.%2052&amp;summary=yes#jcite">52</a> ("[T]he court must find the facts
specially and state its conclusions of law separately."); <i>see also</i>
<i>Transmatic, Inc. v. Gulton Indus., Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3I9HM?jcsearch=53%20f%203d%201270&amp;summary=yes#jcite">53 F.3d 1270</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3I9HM?jcsearch=53%20f%203d%201270&amp;summary=yes#jcite">1275</a> (Fed.Cir.1995)
("When, as here, trial is held before the district court with an advisory
jury, the court must find the facts specially just as it would when
conducting a bench trial without an advisory jury." (citing <i>In re Incident</i>
<i>Aboard the D/B Ocean King</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABQNS?jcsearch=758%20f%202d%201063&amp;summary=yes#jcite">758 F.2d 1063</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABQNS?jcsearch=758%20f%202d%201063&amp;summary=yes#jcite">1072</a> (5th Cir.1985))). And, rather
than filing a motion to have the judgment amended under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L42003?jcsearch=Fed.%20R.%20Civ.%20P.%2052(b)&amp;summary=yes#jcite">Rule 52(b)</a>,
<span CLASS="page_no" data-cite="688 f 3d 1358" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1358" data-primary-citation="688 F3d 1342">[*1358]</span> 
which applies to actions tried before a Rule 39(c)(1) advisory jury, S &amp; N
filed a motion pursuant to Rule 50, which governs "judgment as a matter of
law in a jury trial."<a HREF="#fn500" name="fnref_fn500">[fn5]</a> Fed.R.Civ.P. <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3U003?jcsearch=Fed.R.Civ.P.%2050&amp;summary=yes#jcite">50</a>. Finally, S &amp; N concedes that the
district court, and we, must defer to the jury's explicit factual findings,
a concession that is inconsistent with its reliance on <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039(c)(1)&amp;summary=yes#jcite">Rule 39(c)(1).</a> It is
clear, therefore, that the court did not <span CLASS="page_no" data-cite="2012 bl 204409 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> use the term "advisory jury" to
denote a Rule 39(c)(1) jury.<a HREF="#fn600" name="fnref_fn600">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As a consequence, all of the cases cited by S &amp; N for the proposition that
there are "no factual findings implied within the advisory verdict [that]
are binding on the district court" are irrelevant because all of the cases
involved actions that are not triable to a jury by right and all addressed
Rule 39(c)(1) advisory juries. <i>E.g., Am. Calcar, Inc. v. Am. Honda Motor</i>
<i>Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FKIQ6003?jcsearch=651%20f%203d%201318&amp;summary=yes#jcite">651 F.3d 1318</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FKIQ6003?jcsearch=651%20f%203d%201318&amp;summary=yes#jcite">1333</a> (Fed.Cir.2011) ("Inequitable conduct is equitable
in nature, with no right to a jury, and the trial court has the obligation
to resolve the underlying facts of materiality and intent." (citation
omitted)); <i>Sheila's Shine Prods., Inc. v. Sheila Shine, Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X45O43?jcsearch=486%20f%202d%20114&amp;summary=yes#jcite">486 F.2d 114</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X45O43?jcsearch=486%20f%202d%20114&amp;summary=yes#jcite">122</a> (5th Cir.1973). Whether the jury's verdict on obviousness gave rise to
implied factual findings is not, therefore, controlled by these cases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The term "advisory jury" can also be used to denote a jury's resolution of
a legal issue that the court can permissibly give to the jury to decide, but
whose ultimate determination is reserved for the court. <i>See e.g.,</i>
<i>Spectralytics, Inc. v. Cordis Corp.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FIK08003?jcsearch=649%20f%203d%201336&amp;summary=yes#jcite">649 F.3d 1336</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FIK08003?jcsearch=649%20f%203d%201336&amp;summary=yes#jcite">1341-42</a> (Fed.Cir.2011);
<i>R.R. Dynamics, Inc. v. A. Stucki Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABMSJ?jcsearch=727%20f%202d%201506&amp;summary=yes#jcite">727 F.2d 1506</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABMSJ?jcsearch=727%20f%202d%201506&amp;summary=yes#jcite">1515</a> (Fed.Cir.1984). As
we have explained:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [I]t is neither error nor dangerous to justice to submit legal
    issues to juries, <i>the submission being accompanied by appropriate</i>
    <i>instructions on the law from the trial judge.</i> The rules relating to
    interrogatories, jury instructions, motions for directed verdict,
    JNOV, and new trial, and the rules governing appeals following jury
    trials, are fully adequate to provide for interposition of the judge
    as guardian of the law at the proper point and when necessary. There
    is no question that the judge must
<span CLASS="page_no" data-cite="688 f 3d 1359" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1359" data-primary-citation="688 F3d 1342">[*1359]</span> 
    remain the ultimate arbiter on the question of obviousness. He or
    she exercises that role first in exercising <span CLASS="page_no" data-cite="104 uspq 2d 1013" data-cite-type="ReporterOfDecisions" data-cite-pageno="1013" data-primary-citation="104 U.S.P.Q.2d 1001">[**1013]</span> the judge's duty of
    giving proper instructions on the law to the jury before it
    considers its verdict. The judge exercises control on the question
    again when presented with a motion for JNOV or new trial. In no
    sense need the judge abdicate the guardianship role.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>R.R. Dynamics</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABMSJ?jcsearch=727%20f%202d%201506&amp;summary=yes#jcite">727 F.2d at 1515</a>. This appears to be the manner in which the
district court used the term "advisory jury." Pre-<i>Trial Conference</i>
<i>Transcript</i> at 16-22 ("[N]o matter how I present this to the jury I have to
make a separate determination as to obviousness."). This conclusion is
buttressed by the fact that the Patent Case Management Judicial Guide, which
the district court explained it reviewed with respect to this issue,
suggests this use of the term "advisory jury." Peter S. Menell et al.,
<i>Patent Case Management Judicial Guide</i> 8-32 (2009) ("[T]he court can submit
only the relevant <i>Graham</i> factors to the jury for its determination through
special interrogatories, with or without an advisory verdict on the legal
question of obviousness, and then determine the ultimate question of
obviousness itself based on the jury's factual determinations.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With this understanding of the district court's use of the term "advisory
jury," we now address S &amp; N's remaining argument regarding the standard of
review. S &amp; N asserts that the district court utilized a Rule 49(a) special
interrogatory verdict form. Based on this <span CLASS="page_no" data-cite="2012 bl 204409 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> contention, S &amp; N asserts that
there are no implied factual findings to which deference is due because a
party waives its right to a jury trial on factual issues for which the party
did not demand a special interrogatory and "factual issues not submitted to
the jury as special interrogatories are deemed decided by the district court
in accordance with the court's judgment." Appellee Br. at 40.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926081" href="#headnote_pq2-dec_926081">[2]</a> S &amp; N is incorrect. First, a court employing a Fed.R.Civ.P. <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=Fed.%20R.%20Civ.%20P.%2049&amp;summary=yes#jcite">49</a> special
verdict form can only require the jury to return such findings as to "each
issue of fact." <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(a)(1)&amp;summary=yes#jcite">Rule 49(a)(1)</a>. Because the ultimate conclusion of
obviousness is a legal question, there is strength to the argument that by
including that question on its verdict form the court chose to employ a
general verdict with answers to written questions governed by <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(b)&amp;summary=yes#jcite">Rule 49(b)</a>. It
is clear that factual findings in support of the general verdict are implied
when a verdict form under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(b)&amp;summary=yes#jcite">Rule 49(b)</a> is used. <i>See Quaker City Gear Works,</i>
<i>Inc. v. Skil Corp.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABP2O?jcsearch=747%20f%202d%201446&amp;summary=yes#jcite">747 F.2d 1446</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABP2O?jcsearch=747%20f%202d%201446&amp;summary=yes#jcite">1453</a> (Fed.Cir.1984) (explaining that when
a Rule 49(a) verdict form includes a legal question, "since the answer to
the legal question necessarily resolves any disputed underlying factual
issues, we have undertaken to review the factual findings on which the legal
conclusion is based, applying the substantial evidence standard." (citation
omitted)). Furthermore, we have indicated that, while it is not error to
submit legal questions to the jury as part of a Rule 49(a) special verdict
form, "since the answer to the legal question necessarily resolves any
disputed underlying factual issues," the court must accept implicit factual
findings upon which the legal conclusion is based when they are supported by
substantial evidence. <i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XABP2O?jcsearch=747%20F.2d%201446&amp;summary=yes#jcite">Id</a>.</i> (citing <i>Connell v. Sears, Roebuck &amp; Co.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3J3CD?jcsearch=722%20f%202d%201542&amp;summary=yes#jcite">722 F.2d 1542</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3J3CD?jcsearch=722%20f%202d%201542&amp;summary=yes#jcite">1550</a> (Fed.Cir.1983)); <i>see also Gaia Techs. Inc. v. Recycled</i>
<i>Prods. Corp.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36I9P?jcsearch=175%20f%203d%20365&amp;summary=yes#jcite">175 F.3d 365</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36I9P?jcsearch=175%20f%203d%20365&amp;summary=yes#jcite">371</a> (5th Cir.1999) ("<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(a)&amp;summary=yes#jcite">Rule 49(a)</a> does not permit
a district court to make findings contrary to the jury verdict."). In
essence, because the district
<span CLASS="page_no" data-cite="688 f 3d 1360" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1360" data-primary-citation="688 F3d 1342">[*1360]</span> 
court included the ultimate question of obviousness on the special verdict
form, all of the factual determinations underlying the ultimate question
were implicitly put to the jury for resolution. Wake Forest did not,
therefore, waive a jury trial on any factual issue not submitted to the jury
in an interrogatory, and the district court was required to accept all
implicit factual findings supporting the jury's conclusion with respect to
the ultimate conclusion of obviousness that were supported by substantial
evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, we review all of the jury's explicit and implicit factual
findings for substantial evidence. We then examine the legal conclusion of
obviousness de novo to determine whether it is correct in light of the
factual findings that we find adequately supported. <i>Jurgens</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31U2G?jcsearch=927%20f%202d%201552&amp;summary=yes#jcite">927 F.2d at 1557</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patent is obvious, and, therefore, invalid "if the differences between
the subject matter sought to be patented and the prior art are such that the
subject matter as a whole would have been obvious at the time the invention
was made to a person having ordinary skill in the art to which Said subject
matter pertains." <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a). Obviousness <span CLASS="page_no" data-cite="2012 bl 204409 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> is a question of law based
on underlying factual findings: (1) the scope and content of the prior art;
(2) the differences between the claims and the prior art; (3) the level of
ordinary skill in the art; and (4) objective indicia of nonobviousness.
<i>Graham</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. at 17-18</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>. A party seeking to invalidate a
patent on the basis of obviousness must "demonstrate 'by clear and
convincing evidence that a skilled artisan would have been motivated to
combine the teachings of the prior art references to achieve the claimed
invention, and that the skilled artisan would have had a reasonable
expectation of success in doing so.'" <i>Procter &amp; Gamble Co. v. Teva Pharm.</i>
<i>USA Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d 989</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">994</a> (<span CLASS="page_no" data-cite="104 uspq 2d 1014" data-cite-type="ReporterOfDecisions" data-cite-pageno="1014" data-primary-citation="104 U.S.P.Q.2d 1001">[**1014]</span> Fed.Cir.2009) (quoting <i>Pfizer, Inc. v. Apotex,</i>
<i>Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1361</a> (Fed.Cir.2007)). While an analysis of any
teaching, suggestion, or motivation to combine elements from different prior
art references is useful in an obviousness analysis, the overall inquiry
must be expansive and flexible. <i>KSR Int'l Co. v. Tekflex, Inc.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">415</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">419</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court has explained, moreover, that the obviousness inquiry requires
examination of all four <i>Graham</i> factors. <i>E.g., Mintz v. Dietz &amp; Watson, Inc.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HP6LM003?jcsearch=679%20f%203d%201372&amp;summary=yes#jcite">679 F.3d 1372</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HP6LM003?jcsearch=679%20f%203d%201372&amp;summary=yes#jcite">1375</a> (Fed.Cir.2012). Indeed, courts must consider all of the
<i>Graham</i> factors prior to reaching a conclusion with respect to obviousness.
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HF6KC003?jcsearch=676%20f%203d%201063&amp;summary=yes#jcite">676 F.3d 1063</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HF6KC003?jcsearch=676%20f%203d%201063&amp;summary=yes#jcite">1076-77</a> (Fed.Cir.2012) (collecting cases). At all times, the
burden is on the defendant to establish by clear and convincing evidence
that the patent is obvious. <i></i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HF6KC003?jcsearch=676%20F.3d%201063&amp;summary=yes#jcite">Id. at 1077-78</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because Wake Forest asserts that the district court erred by granting
judgment as a matter of law overturning the jury's verdict, we must
determine which of the jury's explicit and implicit factual findings with
respect to the <i>Graham</i> factors are supported by substantial evidence. Each of
the <i>Graham</i> factors is addressed in turn below.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Scope and Content of the Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties agree on which references are prior art. On appeal, S &amp; N
<span CLASS="page_no" data-cite="688 f 3d 1361" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1361" data-primary-citation="688 F3d 1342">[*1361]</span> 
focuses its obviousness analysis on the Bagautdinov references, Zamierowski
reference, and the Chariker-Jeter references. With respect to these
references, the parties dispute their content,<a HREF="#fn700" name="fnref_fn700">[fn7]</a> namely, whether the
prior art discloses the treatment of wounds with negative pressure. This is
the central issue on appeal because all of the asserted claims, covering
either the method or apparatus, require the use of negative pressure to
either "treat a wound" or "facilitate the healing of wound."<a HREF="#fn800" name="fnref_fn800">[fn8]</a> The
district court concluded that there was no support for the proposition that
these primary references did not disclose the treatment of wounds utilizing
negative pressure. <i>JMOL Order</i> at 25, 27-28, 33. As explained below, this was
error: substantial evidence supports the jury's implied factual finding that
none of these references disclosed the treatment of wounds using negative
pressure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. Content of the Bagautdinov References
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Bagautdinov references disclose a device for draining fluid from
purulent wounds. The device involves placement of a polyurethane foam in the
purulent wound, attaching the foam to a pump, and covering the apparatus and
the wound with a <span CLASS="page_no" data-cite="2012 bl 204409 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> polyethylene film secured to the skin with vaseline oil.
J.A. 10002.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926082" href="#headnote_pq2-dec_926082">[3]</a> The jury was presented with conflicting evidence regarding whether the
references treated wounds as construed by the district court, and if they
did, whether they treated wounds with negative pressure. S &amp; N's experts
contended that the references disclosed the treatment of wounds within the
meaning of the asserted claims. <i>See</i> J.A. 22345:13-17 (testimony of Dr.
Gordon, S &amp; N's expert, stating that Bagautdinov I disclosed the use of
negative pressure to treat a wound). In addition, Dr. Bagautdinov displayed
the method disclosed in the references to the jurors with the aid of a
manikin. J.A. 22204-05.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest presented conflicting testimony, however. It proffered expert
testimony that the purulent wounds described in the Bagautdinov references
are in fact abscess or pus pockets not within the district court's
construction of the term "wound." J.A. 22871:19-21 ("Dr. Bagautdinov is
using a variant, or modification of a technique, to aspirate, or to suck
out, pus from a purulent wound, which is a pus pocket."); J.A. 21431:15-23
(discussing how Bagautdinov treated pus pockets by lancing and then draining
them with the disclosed method). In addition, Wake Forest's expert testified
that the Bagautdinov references indicate that use of the device is
discontinued when the purulent wound has been cleaned of infection, whereas
the patented method and apparatus are utilized only after a wound has been
cleaned of infection. J.A. 22878:7-80:16. S &amp; N's expert conceded,
more-over, that the Bagautdinov articles were "particularly concerned about
the problems related to putting negative pressure on the area of skin
surrounding the wound and the risk of spreading infection, causing tissue
damage. . . ." J.A. 22343:5-8. In
<span CLASS="page_no" data-cite="688 f 3d 1362" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1362" data-primary-citation="688 F3d 1342">[*1362]</span> 
other words, the Bagautdinov references explain that use of negative
pressure on or surrounding a wound is dangerous to the patient. This amounts
to teaching away. <i>Ricoh Co. v. Quanta Computer Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AACQ6003?jcsearch=550%20f%203d%201325&amp;summary=yes#jcite">550 F.3d 1325</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AACQ6003?jcsearch=550%20f%203d%201325&amp;summary=yes#jcite">1332</a>
(<span CLASS="page_no" data-cite="104 uspq 2d 1015" data-cite-type="ReporterOfDecisions" data-cite-pageno="1015" data-primary-citation="104 U.S.P.Q.2d 1001">[**1015]</span> Fed.Cir.2008) (quoting <i>In re Kahn</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X14IJGC003?jcsearch=441%20f%203d%20977&amp;summary=yes#jcite">441 F.3d 977</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X14IJGC003?jcsearch=441%20f%203d%20977&amp;summary=yes#jcite">990</a> (Fed.Cir.2006) ("A
reference may be said to teach away when a person of ordinary skill, upon
reading the reference, would be discouraged from following the path set out
in the reference, or would be led in a direction divergent from the path
that was taken by the applicant.")).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Wake Forest presented testimony that the method disclosed in the
Bagautdinov references could not create an adequate seal, J.A.
21437:25-38:2; J.A. 21433:2-15, and did not treat wounds through negative
pressure because the pressure was not sustained for a long enough period of
time. J.A. 21433:18-34:11; J.A. 21437:19-38:2. Indeed, Dr. Bagautdinov
admitted that he only used his device to treat "infected wounds," J.A.
22312:15-22, and that he "never considered using [his] technique to treat
wounds until closure." J.A. 22310:17-21.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because of this conflicting expert testimony, the jury was free to "make
credibility determinations and believe the witness it considers more
trustworthy." <i>Streber v. Hunter</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3ITO6?jcsearch=221%20f%203d%20701&amp;summary=yes#jcite">221 F.3d 701</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3ITO6?jcsearch=221%20f%203d%20701&amp;summary=yes#jcite">726</a> (5th Cir.2000)
(quotations omitted). In light of the jury's determination that S &amp; N failed
to prove obviousness, we must infer <span CLASS="page_no" data-cite="2012 bl 204409 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> that the jury found Wake Forest's
experts to be credible and persuasive on this point. <i>Broussard</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18NPFC003?jcsearch=523%20f%203d%20618&amp;summary=yes#jcite">523 F.3d at 624</a>; <i>Jurgens</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31U2G?jcsearch=927%20f%202d%201552&amp;summary=yes#jcite">927 F.2d at 1557</a>. Crediting their testimony over
that of S &amp; N's expert, there is substantial evidence supporting the factual
finding that the Bagautdinov references do not disclose: (1) the treatment
of "wounds" as described in patents; or (2) use of negative pressure to
treat wounds. There is also substantial evidence to support the finding that
the references teach away from maintaining negative pressure on a wound for
extended periods of time because of the perceived problems associated with
doing so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. Content of the Zamierowski Reference
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties agree that the Zamierowski reference's method is utilized on
"wounds" within the district court's construction, and discloses placing a
screen means into a wound, sealing the wound by placing a membrane with an
adhesive coating over the wound, and connecting a tube from under the
membrane to a vacuum source. J.A. 28. This system can then be used to either
drain from or inject fluid into the wound. J.A. 10063. S &amp; N argues, and the
district court found, that the Zamierowski reference also disclosed treating
wounds with negative pressure. <i>JMOL Order</i> at 27-28.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During trial, Wake Forest argued that this reference does not disclose
healing wounds with negative pressure because it neither disclosed a seal
capable of maintaining negative pressure on a wound, nor disclosed treating
the wound towards a selected stage of healing as required by the asserted
method claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court concluded that Wake Forest's first argument was
incorrect because it found that the patent claims do not require healing to
be accomplished by negative pressure. <i></i><cite>Id. at 27</cite>. In the alternative, the
district court concluded that the Zamierowski reference met this requirement
because fluid is removed from the wound with negative pressure and removal
<span CLASS="page_no" data-cite="688 f 3d 1363" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1363" data-primary-citation="688 F3d 1342">[*1363]</span> 
of fluid enabled healing, so "healing" was "accomplished by the negative
pressure." <i></i><cite>Id. at 27-28</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926083" href="#headnote_pq2-dec_926083">[4]</a> The district court was incorrect with respect to its determination that
the claims of the asserted patents do not require wounds to be healed by
negative pressure. First, in the <i>Blue Sky</i> appeal, we concluded that all of
the claims of the '<cite>081 patent</cite> asserted in the present litigation require the
use of negative pressure to treat a "wound." <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d at 1015</a> ("[E]ach of
the asserted claims in both the '<cite>081</cite> and '<cite>643 patents</cite> requires using
'reduced' or 'negative' pressure to 'treat a wound' or 'facilitate the
healing of a wound. . . .'"). Thus, we have already construed the claims to
include this limitation and that legal conclusion was binding on the
district court and is binding on this panel. The specifications of both the
'<cite>081</cite> and '<cite>651</cite> patents support our conclusion in <i>Blue Sky</i>, moreover. <i>E.g.</i>,
'<cite>081 patent</cite> col. 2 ll.45-49 ("The present invention includes . . . applying
a negative pressure to a wound over an area sufficient to promote migration
of epithelial and subcutaneous tissue toward the wound, with the negative
pressure being maintained for a time sufficient to facilitate closure of the
wound."); '<cite>651 patent</cite> col. 2 ll.<span CLASS="page_no" data-cite="2012 bl 204409 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> 61-64 ("[A] wound treatment apparatus is
provided for treating a wound by applying reduced pressure . . . to the
wound. . . ."). And, before the PTO, the patentees distinguished their
claims from the prior art by asserting that references "do not disclose or
suggest 'an appliance for administering a reduced pressure treatment to a
wound'; 'an apparatus/method for treating a wound' with reduced pressure."
J.A. 5501 ('<cite>651 patent</cite>); <i>see also</i> J.A. 5502 ('<cite>651 patent</cite>); J.A. 8267 ('<cite>081
patent</cite>) (Unlike the prior art, "[the] claimed invention is directed to a
device configured to create and maintain negative pressure on a wound site .
. . for the purpose of administering a negative pressure treatment to the
wound."). Finally, S &amp; N never argued before the district court that the
asserted claims did not require this limitation. In light of our prior
holding in <i>Blue Sky<span CLASS="page_no" data-cite="104 uspq 2d 1016" data-cite-type="ReporterOfDecisions" data-cite-pageno="1016" data-primary-citation="104 U.S.P.Q.2d 1001">[**1016]</span> </i>, the language of the specification, and the patentee's
statements made during reexamination, we find that each of the asserted
claims requires the use of negative pressure to heal or treat wounds.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to the district court's alternative holding, whether the
prior art discloses the limitations of a particular claim is a question of
fact to be determined by the jury, and Wake Forest presented ample evidence
that the Zamierowski reference does not disclose the use of negative
pressure to heal wounds. J.A. 21453:19-25; J.A. 22667:24-70:10; J.A.
22866:19-58:12.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In support of its argument that the Zamierowski reference does not
disclose a seal capable of maintaining negative pressure, Wake Forest
presented testimony that the reference does not create a seal within the
meaning of the patent because it uses only a tight liquid seal that has air
gaps. J.A. 21472:19-73:11; J.A. 22668:25-69:4. This testimony is consistent
with the reference, which indicates that the dressing material is
"breathable semipermeable" and the seal is "relatively liquid-tight." J.A.
10068; J.A. 10070. With respect to the contention that "healing" is not
accomplished as contemplated by the patents, Wake Forest's expert testified
that the Zamierowski reference failed to disclose maintaining negative
pressure until the wound has progressed to a selected stage of healing. J.A.
22456:24-58:1; J.A. 22669:5-8. Zamierowski, instead, uses a
<span CLASS="page_no" data-cite="688 f 3d 1364" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1364" data-primary-citation="688 F3d 1342">[*1364]</span> 
tubing system to medicate and drain wounds, and thereby "promote[] healing"
generally, J.A. 10061-63; J.A. 10074; it does not disclose the use and
maintenance of negative pressure on a wound site to facilitate wound closure
and thereby promote wound healing, as do the patents. And, unlike the system
specified in the patents, Zamierowski's system is to be removed once the
process of medication and draining has been completed. J.A. 10073. Indeed,
the inventor of the Zamierowski device testified that the inventors of the
'<cite>651</cite> and '<cite>081 patents</cite> invented the use of negative pressure for wound
therapy and that he had not. J.A. 22571:13-17; <i>see also</i> J.A. 22571:10-12
(Zamierowski inventor indicating that his contribution to the commercial
embodiment of the asserted patents is primarily the methods of attaching the
"the rigid conduit to the flimsy film").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because <span CLASS="page_no" data-cite="2012 bl 204409 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> the jury concluded that S &amp; N failed to establish that the patents
were obvious, we must assume that the jury found Wake Forest's expert to be
credible and persuasive on this point. In light of this assumption, there is
substantial evidence to support the factual finding that the Zamierowski
reference does not disclose a sealing means capable of maintaining negative
pressure, or maintenance of pressure until the wound has progressed toward a
selected stage of healing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  3. Content of the Chariker-Jeter References
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Chariker-Jeter references, as explained above, disclose a system for
treating wounds that are complicated by a fistula. J.A. 10043. The parties
dispute whether these references disclose the treatment of a wound within
the meaning of the patents, and if it does disclose treatment of such
wounds, whether the disclosed device used negative pressure to treat the
wounds. With the exception of the Chariker-Jeter public use, the two
Chariker-Jeter publications indisputably deal only with the treatment of
"[p]atients with draining wounds and fistulae." J.A. 10050.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926084" href="#headnote_pq2-dec_926084">[5]</a> In <i>Blue Sky</i>, we held that the term wound, as used in these patents "does
not cover the fistulae described in the [Chariker-Jeter] publications. . .
." <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d at 1018</a>. Despite our conclusion that the in-juries treated in
the Chariker-Jeter publications are not "wounds" within the meaning of these
patents, S &amp; N presented testimony attempting to establish that the
references disclosed such treatment. J.A. 22348:1-49:12; J.A. 22028:7-30:6.
Regarding the Chariker-Jeter public use, which was not addressed in <i>Blue</i>
<i>Sky</i>, S &amp; N proffered the testimony of Dr. Chariker who, while he was a
resident, helped treat Mr. Aderholt with the system disclosed in the
Chariker-Jeter publications. In this testimony, Dr. Chariker testified that
he used the system to heal Mr. Aderholt with negative pressure. J.A.
22032:2-38:11.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wake Forest presented testimony to contradict S &amp; N's evidence. Its expert
testified that all of the patients mentioned in the Chariker-Jeter
publications had fistulae, and therefore, that the publications do not
disclose the treatment of wounds within the district court's construction.
J.A. 21441:1-7; J.A. 22672:11-23. In fact, on cross examination Dr. Chariker
admitted that neither of the Chariker-Jeter publications discloses wounds
not involving a fistula. J.A. 22045:15-25. Wake Forest's experts testified,
moreover, that the device disclosed in the Chariker-Jeter references did not
use negative pressure to treat wounds. J.A. 22671:12-91:24; JA.
21439:1-41:22; <span CLASS="page_no" data-cite="688 f 3d 1365" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1365" data-primary-citation="688 F3d 1342">[*1365]</span> J.A. 22869:13-70:21. And,

Wake Forest's expert testified that the Chariker-Jeter publications actually
taught to limit granulization, which is directly contrary to the purpose of
the '65L and '081 patents. JA 21441:12-19 ("So. according to their document,
they seem to want to limit granulation tissue formation."); J.A. 22673:11-12
("[Drs. Chariker and Jeter] actually wanted to inhibit granulation
tissue.").
<span CLASS="page_no" data-cite="104 uspq 2d 1017" data-cite-type="ReporterOfDecisions" data-cite-pageno="1017" data-primary-citation="104 U.S.P.Q.2d 1001">[**1017]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Significantly, Dr. Chariker conceded that he "didn't publish anything
about negative pressure wound therapy regarding fistulas or nonfistulas."
J.A. 22046:8-9. Similarly, <span CLASS="page_no" data-cite="2012 bl 204409 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> Dr. Jeter admitted on cross examination that she
never suggested using the disclosed device if there was nothing to drain.
J.A. 22147:8-11.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to the Chariker-Jeter public use, Wake Forest offered
testimony that Mr. Aderholt's wound involved a fistula, so it was not a
wound within the meaning of the patents. J.A. 22696:4-13; J.A.
22698:22-99:5; J.A. 22898:22-99:8. On cross examination, moreover, Dr.
Chariker refused to say that Mr. Aderholt did not have a fistula; he only
stated that one was never diagnosed. J.A. 22057:23; J.A. 22058:4; J.A.
22085:2-6. In addition, Wake Forest's expert testified that, based on his
reading of Mr. Aderholt's operative notes and pictures of his treatment, the
system used on Mr. Aderholt was not the system disclosed in the
Chariker-Jeter publications. J.A. 22714:25-15:9. Wake Forest's expert also
testified that the Chariker-Jeter public use did not have a seal capable of
maintaining negative pressure because Mr. Aderholt's skin had several sump
drains that freely let air flow. J.A. 2900:14-02:14. In other words, his
wound was not healed with negative pressure, J.A. 2712:13-14:19.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Wake Forest's experts testified that use of the drainage system
disclosed in the Chariker-Jeter publications was discontinued when the
fistula closed or substantial drainage from the fistula stopped,
irrespective of the state of any wound healing. J.A. 22869:20-70:12; J.A.
21438:13-39:18; J.A. 22672:24-74:4; J.A. 22870:3-5 ("In every single case,
every single case that they show in the book chapter and in the article, the
minute the fistula stopped draining, they got rid of their device."). Dr.
Chariker conceded this fact on cross examination. J.A. 22062:17-20. This,
again, reasonably could be deemed a teaching away from continued long-term
use of the device, as directed by the '081 and '<cite>651</cite> patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Again, because of the procedural posture of this case, we must assume that
the jury found Wake Forest's experts credible and persuasive. Rather than
credit this testimony, however, the district court impermissibly reweighed
witness credibility, concluding that Wake Forest's expert's testimony that
Mr. Aderholt had a fistula was "completely unsupported by the evidence."
<i>JMOL Order</i> at 32. This was error. <i>See Blue Sky</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d at 1020</a>. On the
basis of this credited testimony, there is substantial evidence to support
the finding that: (1) none of the Chariker-Jeter references discloses
treatment of a wound within the meaning of the patents (as distinct from a
fistula or pus pocket); (2) the Chariker-Jeter references do not disclose
use of negative pressure to heal or treat wounds<a HREF="#fn900" name="fnref_fn900">[fn9]</a>; (3) the
Chariker-Jeter publications teach away from promoting
<span CLASS="page_no" data-cite="688 f 3d 1366" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1366" data-primary-citation="688 F3d 1342">[*1366]</span> 
healing by using negative pressure; (4) the Chariker-Jeter public use did
not involve the device disclosed in the Chariker-Jeter publications; and (5)
the public use did not involve a seal capable of maintaining negative
pressure. Finally, with respect to the method claims, substantial evidence
supports the finding that negative pressure was not maintained until the
wound progressed toward a selected stage of healing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Level of Ordinary Skill in the Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926085" href="#headnote_pq2-dec_926085">[6]</a> Although the <span CLASS="page_no" data-cite="2012 bl 204409 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> parties did not stipulate the level of ordinary skill in the
art, S &amp; N's expert testified that the level of ordinary skill in the art
"would include health care professionals, for example physicians or nurses,
but it could be a podiatrist or somebody else, who has additional training
or knowledge about wound care. It could also be engineers with experience
operating or designing equipment used in conjunction with wound care." J.A.
22340:8-13. According to the district court, Wake Forest asserted that the
level of skill was higher. J.A. 393. Because it is generally easier to
establish obviousness under a higher level of ordinary skill in the art,
<i>Innovention Toys, LLC v. MGA Entm't, Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1F5448003?jcsearch=637%20f%203d%201314&amp;summary=yes#jcite">637 F.3d 1314</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1F5448003?jcsearch=637%20f%203d%201314&amp;summary=yes#jcite">1323</a>
(Fed.Cir.2011) ("A less sophisticated level of skill generally favors a
determination of nonobviousness, and thus the patentee, while a higher level
of skill favors the reverse." (citation omitted)), we must assume that, in
light of the jury's verdict, it adopted the lower level of skill proposed by
S &amp; N.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. Differences Between the Claimed Invention and the Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury explicitly found that the prior art and the asserted claims
exhibited several differences, which S &amp; N conceded existed. J.A. 65-69. In
addition, the jury stated that each of the prior art references exhibited
additional differences from those explicitly mentioned on the verdict form,
although they were not asked to and, thus, did not identify those additional
differences.
<span CLASS="page_no" data-cite="104 uspq 2d 1018" data-cite-type="ReporterOfDecisions" data-cite-pageno="1018" data-primary-citation="104 U.S.P.Q.2d 1001">[**1018]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926086" href="#headnote_pq2-dec_926086">[7]</a> Although there are many differences between the primary prior art
references and the asserted claims, for the purpose of this appeal, we need
only focus on three. As discussed above, substantial evidence supports the
finding that none of the references discloses treating wounds with negative
pressure as required by the patents. Nor do the Bagautdinov and
Chariker-Jeter references relate to the treatment of wounds described in the
patents, as construed by this court in <i>Blue Sky</i> and the district court here.
Finally, the Bagautdinov references and the Zamierowski reference do not
disclose a seal capable of maintaining negative pressure. Accordingly, none
of the references discloses healing or treatment with negative pressure.
Only the Zamierowski reference discloses treating or healing wounds and only
the Chariker-Jeter printed publications disclose a seal that is capable of
maintaining pressure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even if the references disclosed all of the limitations of the asserted
claims, which they do not, S &amp; N still needed to proffer evidence indicating
why a person having ordinary skill in the art would combine the references
to arrive at the claimed invention. <i>Innogenetics, N.V. v. Abbott Labs.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18DIMI003?jcsearch=512%20f%203d%201363&amp;summary=yes#jcite">512 F.3d 1363</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18DIMI003?jcsearch=512%20f%203d%201363&amp;summary=yes#jcite">1374</a> (Fed. <span CLASS="page_no" data-cite="688 f 3d 1367" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1367" data-primary-citation="688 F3d 1342">[*1367]</span> Cir.2008)

(holding that post-KSR "some kind of motivation must be shown from some
source, so that the jury can understand why a person of ordinary skill would
have thought of either combining two or more references or modifying one to
achieve the patented [invention]." (citation omitted)). Significantly,
whether there is a reason to combine prior art references is a question of
fact. <i>Transocean Offshore Deepwater Drilling, <span CLASS="page_no" data-cite="2012 bl 204409 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> Inc. v. Maersk Contractors USA</i>
<i>Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">617 F.3d 1296</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">1303</a> (Fed.Cir.2010) (citing <i>McGinky v. Franklin Sports,</i>
<i>Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5150M?jcsearch=262%20f%203d%201339&amp;summary=yes#jcite">262 F.3d 1339</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X5150M?jcsearch=262%20f%203d%201339&amp;summary=yes#jcite">1352</a> (Fed. Cir.2001)). Here, not only did S &amp; N offer
no evidence establishing a reason to combine, but Wake Forest offered
substantial evidence that a person having ordinary skill in the art had no
reason to combine the prior art references to arrive at the claimed
invention. <i>E.g.</i>, J.A. 22669:18-25; J.A. 22691:18-22; J.A. 22715:25-16:4;
J.A. 22737:7-11; J.A. 22753:24-54:3. In light of the jury's verdict, we must
assume that it determined there was no reason to combine the prior art
references, and we must defer to this factual finding because it is
supported by substantial evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  D. Objective Indicia of Nonobviousness
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to the '081 asserted claims, the jury found the following
indicia of nonobviousness: (1) commercial success; (2) long felt need; (3)
copying; (4) unexpected results; (5) acceptance by others; and (6) initial
skepticism. With respect to the '651 asserted claims, the jury found that
for claims 109 and 116 on the basis of performing the method of claim 42,
and claim 121 on the basis of performing the method of claim 42, the same
indicia of nonobvious were present. Regarding claim 116, on the basis of
performing the method of claim 20, and claim 121, on the basis of performing
the method of claim 20, the jury concluded that only copying existed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926087" href="#headnote_pq2-dec_926087">[8]</a> Wake Forest presented testimony regarding each of the objective indicia
found by the jury. J.A. 22827:3-32:10; J.A. 217771:11-23; J.A.
21077:19-79:15. Wake Forest offered evidence that leading experts in the
field were skeptical that the "counterintuitive" device could work. J.A.
22827:3-12, J.A. 22828:21-29:23, J.A. 21078:4-79:5. One expert testified
that he "didn't know how you could put this [negative] pressure on a wound
and not cut off the blood supply, not cause infection, etc." J.A. 22827:3-9.
Indeed, Dr. Argenta, an inventor of the patents, testified that the hospital
where he worked was concerned about allowing him to try his device on a
patient with a serious wound, which could not be healed with conventional
methods, but the "decision [was] do you let [the patient] die or do you try
something." J.A. 20446:3-23. To everyone's surprise, the device completely
healed this patient. J.A. 20446:21-47:6. The medical community was so
skeptical of the device, moreover, that the patents' inventors had
difficulty publishing their findings in peer-reviewed journals, J.A.
20501:1-19 (Reviewers from the journal <i>Plastic and Reconstructive Surgery</i>
stated that "there was no way that this was possible, that this device could
do this"), and they were turned away by conference organizers when they
attempted to present the discovery. J.A. 20502:10-15; J.A. 20501:3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite this initial skepticism, over time the device was widely adopted
and praised. J.A. 22830:6-31:8, J.A. 21079:10-12. Wake Forest presented
testimony from experts that the patented device "changed the way we do
surgery," J.A. 21079:11-12, and "changed the way . . . we've been treating
wounds for the last twenty, thirty years." <span CLASS="page_no" data-cite="688 f 3d 1368" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1368" data-primary-citation="688 F3d 1342">[*1368]</span> J.A. 22831:1-3. Indeed,

S &amp; N's own expert testified that the device was "a paradigm shift in wound
healing" and that it "is so effective that it's changed <span CLASS="page_no" data-cite="2012 bl 204409 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> the way that [he]
and [his] fellow surgeons treat serious wounds." J.A. 22409:11-10:11. To
date, the device has been used on more than three million patients. J.A.
21753:22-25. Indeed, Harvard Medical School called the device an "exciting
novel therapeutic approach to wounds," J.A. 20504:22-05:2, and the American
Association of Plastic Surgeons recognized the device as the last decade's
"biggest <span CLASS="page_no" data-cite="104 uspq 2d 1019" data-cite-type="ReporterOfDecisions" data-cite-pageno="1019" data-primary-citation="104 U.S.P.Q.2d 1001">[**1019]</span> advance in the plastic surgery field." J.A. 22762:10-15. The
effectiveness of the device and this praise has made it a commercial success
with $1.4 billion in annual sales. J.A. 21771:12-13.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, Wake Forest proffered testimony that the device has been copied.
For example, in internal documents and marketing materials, S &amp; N repeatedly
compares its products to the V.A.C., the commercial embodiment of the
patents. J.A. 22760:11-61:23; J.A. 20537:17-39:18; J.A. 20999:1-21. Indeed,
S &amp; N's expert admitted that he authored an article explaining how to create
"an off-the-shelf or makeshift V.A.C." J.A. 22410:18-12:6.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the face of this evidence, S &amp; N offered no rebuttal evidence. S &amp; N's
own invalidity expert even admitted that he did not consider the objective
indicia of nonobviousness in reaching his conclusions regarding the
invalidity of the patents. J.A. 22396:20-97:8; J.A. 22415:24-16:15.
Significantly, the district court concluded that Wake Forest "present[ed]
ample evidence of success of V.A.C. product and the other secondary
considerations tending to show non-obviousness." J.A. 3.7. On the basis of
this record, there is more than substantial evidence supporting the jury's
findings of commercial success, long-felt need, copying, unexpected and
superior results, wide spread acceptance in the field, and initial
skepticism.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  E. The Ultimate Conclusion of Obviousness
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having determined that the jury's explicit and several implicit factual
findings are supported by substantial evidence, "we examine the [ultimate]
legal conclusion [of obviousness] de novo to see whether it is correct in
light of these factual findings. <i>Jurgens</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31U2G?jcsearch=927%20f%202d%201552&amp;summary=yes#jcite">927 F.2d at 1557</a> (internal
citations omitted); <i>see also Wyers v. Master Lock Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">616 F.3d 1231</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">1248</a>
(Fed.Cir.2010) (Linn, J., concurring). Despite the district court's detailed
analysis, we find that, on the basis of the jury's factual findings, it
erred by granting S &amp; N's Motion for JMOL.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the Supreme Court made clear that a mechanical application of the
teaching-suggestion-motivation test, requiring an explicit teaching in the
prior art, is inappropriate, "[w]e must still be careful not to allow
hindsight reconstruction of references to reach the claimed invention
without any explanation as to how or why the references would be combined to
produce the claimed invention." <i>Innogenetics</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18DIMI003?jcsearch=512%20f%203d%201363&amp;summary=yes#jcite">512 F.3d at 1374</a> n. 3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_926088" href="#headnote_pq2-dec_926088">[9]</a> As noted above, S &amp; N never offered evidence articulating why a person
having

<span CLASS="page_no" data-cite="688 f 3d 1369" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1369" data-primary-citation="688 F3d 1342">[*1369]</span> ordinary skill in the art would combine the primary references to obtain the
disclosed inventions. Although expert testimony regarding motivation to
combine is not always required, the technology at issue here is not the type
of technology where common sense would provide the motivation to combine
these references. <i>See Master Lock Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">616 F.3d at 1240</a> n. 5 ("However, as
we [<span CLASS="page_no" data-cite="2012 bl 204409 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> have] noted . . . 'expert testimony regarding matters beyond the
comprehension of laypersons is sometimes essential,' particularly in cases
involving complex technology. In such cases, expert testimony may be
critical, for example, to establish . . . the existence (or lack thereof) of
a motivation to combine references." (internal citations omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At a minimum, creation of the claimed apparatus or method requires
combining the Zamierowski references, which disclose treating or healing of
wounds, with the Chariker-Jeter publications that disclose a seal capable of
maintaining negative pressure. The record is devoid of any reason someone
would combine these references, however. Indeed, Wake Forest's experts
testified that there was no reason to combine them. J.A. 22865:15-66:17;
J.A. 22868:13-69:19; J.A. 22870:22-71:12. In addition, both of these
references independently accomplish similar functions, namely, draining
fluids. Because each device independently operates effectively, a person
having ordinary skill in the art, who was merely seeking to create a better
device to drain fluids from a wound, would have no reason to combine the
features of both devices into a single device. Nor do the Bagautdinov
references provide such motivation to combine the Zamierowski references and
the Chariker-Jeter publications to arrive at the method and apparatus
claimed in the patents in suit. Again, the Bagautdinov references disclose
only the draining of purulent wounds; it says nothing about treating wounds
within the district court's construction, much less the healing of such
wounds with negative pressure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As Dr. Argenta noted, moreover, if any of the doctors who created the
devices disclosed in the prior art thought that negative pressure actually
healed wounds, they would have left the devices in place until the wounds
were fully healed. J.A. 22870. All of the doctors removed the devices after
the wounds were drained, but before healing with negative <span CLASS="page_no" data-cite="104 uspq 2d 1020" data-cite-type="ReporterOfDecisions" data-cite-pageno="1020" data-primary-citation="104 U.S.P.Q.2d 1001">[**1020]</span> pressure began.
This indicates that the doctors were not using the disclosed devices and
methods to heal wounds with negative pressure because they did not believe
that these devices were capable of such healing. In fact, several of the
primary references disclosed methods that purposefully minimize
granulization while the devices were in place because of the perceived
dangers associated with negative pressure. This amounts to significant
evidence of teaching away. On the basis of this evidence, hind-sight
provides the only discernable reason to combine the prior art references.
Unless one knew that negative pressure could be used to treat wounds, there
would be no reason to combine the prior art to arrive at the claimed device
and methods.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is clear, moreover, that the district court concluded that the
invention was obvious because it believed the claims contained elements that
were not new. This reasoning is incorrect: "a patent composed of several
elements is not proved obvious merely by demonstrating that each of its
elements was, independently, known in the <span CLASS="page_no" data-cite="2012 bl 204409 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> prior art." <i>KSR</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 418</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>. Because none of the prior art references disclosed utilizing
negative pressure to heal wounds, this is not even a
<span CLASS="page_no" data-cite="688 f 3d 1370" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1370" data-primary-citation="688 F3d 1342">[*1370]</span> 
case where the inventions at issue are merely: composed of elements that
were known in the art. Indeed, nearly seven years after the '<cite>081 patent</cite> was
filed, Dr. Attinger testified that he still did not believe the apparatus
and method disclosed in the patents would work. J.A. 22827:3-29:2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the significant objective indicia of nonobviousness strongly
weigh against a finding of obviousness. <i>Mintz</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HP6LM003?jcsearch=679%20f%203d%201372&amp;summary=yes#jcite">679 F.3d at 1378</a> (Evidence of
objective indicia of non-obviousness "may often establish that an invention
appearing to have been obvious in light of the prior art was not." (citation
omitted)); <i>In re Cyclobenzaprine</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HF6KC003?jcsearch=676%20f%203d%201063&amp;summary=yes#jcite">676 F.3d at 1075-76</a> (same); <i>see also</i>
<i>Crocs, Inc. v. Int'l Trade Comm'n</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1CJGMG003?jcsearch=598%20f%203d%201294&amp;summary=yes#jcite">598 F.3d 1294</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1CJGMG003?jcsearch=598%20f%203d%201294&amp;summary=yes#jcite">1310</a> (Fed.Cir.2010)
("Secondary considerations 'can be the most probative evidence of
non-obviousness in the record, and enables the . . . court to avert the trap
of hindsight.' ") (quoting <i>Custom Accessories, Inc. v. Jeffrey-Allan Indus.,</i>
<i>Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4ADEH?jcsearch=807%20f%202d%20955&amp;summary=yes#jcite">807 F.2d 955</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4ADEH?jcsearch=807%20f%202d%20955&amp;summary=yes#jcite">960</a> (Fed.Cir.1986)); <i>Ortho-McNeil Pharm., Inc. v. Mylan</i>
<i>Labs., Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">520 F.3d 1358</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">1365</a> (Fed.Cir.2008) ("Objective indicia may
often be the most probative and cogent evidence of nonobviousness in the
record.") (quoting <i>Catalina Lighting, Inc. v. Lamps Plus, Inc.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XADUR4?jcsearch=295%20f%203d%201277&amp;summary=yes#jcite">295 F.3d 1277</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XADUR4?jcsearch=295%20f%203d%201277&amp;summary=yes#jcite">1288</a> (Fed.Cir.2002) (citation omitted)). We require analysis
of the objective indicia because they "provide objective evidence of how the
patented device is viewed in the marketplace, by those directly interested
in the product." <i>Demaco Corp. v. F. Von Langsdorff Licensing Ltd.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XAFJEH?jcsearch=851%20f%202d%201387&amp;summary=yes#jcite">851 F.2d 1387</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XAFJEH?jcsearch=851%20f%202d%201387&amp;summary=yes#jcite">1391</a> (Fed.Cir.1988). As discussed above, the medical
community scoffed at this device when it was initially introduced. The
industry was skeptical that the device worked even after reading studies
that established that it did in fact work. J.A. 21078:19-21079:5. After the
system was disseminated, moreover, everyone began using it, and the method
and apparatus were copied. This evidence provides a key objective insight
into how the medical community viewed the patented device.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Significantly, this is not a case where the jury found the presence of
only one or two objective indicia of nonobviousness. Nor is it a case where
S &amp; N seriously disputes those findings. Rather, the evidence strongly
establishes the existence of nearly every objective indicia of
nonobviousness, namely commercial success, long-felt need, copying,
unexpected and superior results, wide spread acceptance in the field, and
initial skepticism. <i>See Allen Archery, Inc. v. Browning Mfg. Co.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X467HN?jcsearch=819%20f%202d%201087&amp;summary=yes#jcite">819 F.2d 1087</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X467HN?jcsearch=819%20f%202d%201087&amp;summary=yes#jcite">1092</a> (Fed.Cir.1987) ("[P]raise from a competitor tends to
indicat[e] that the invention was not obvious." (alteration in original)
(internal quotation omitted)); <i>Gambro Lundia AB v. Baxter Healthcare Corp.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31Q3I?jcsearch=110%20f%203d%201573&amp;summary=yes#jcite">110 F.3d 1573</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X31Q3I?jcsearch=110%20f%203d%201573&amp;summary=yes#jcite">1579</a> (Fed.Cir.1997) (acknowledging that the accused
infringer's "recognition of the importance of this advance is relevant to a
determination of nonobviousness."). We recently warned about the dangers of
ignoring objective indicia of nonobviousness in <i>Mintz</i>, where we said:
"[s]imply because the technology can be easily understood does not mean that
it will satisfy the legal standard of obviousness. In fact, objective
consideration of simple technology <span CLASS="page_no" data-cite="2012 bl 204409 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> is often the most difficult because, once
the problem and solution appear together in the patent disclosure, the
advance seems self-evident." <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1HP6LM003?jcsearch=679%20f%203d%201372&amp;summary=yes#jcite">679 F.3d at 1379</a>. The objective indicia of
nonobviousness serve a particularly important role in a case, like this one,
where there is a battle of scientific experts regarding the obviousness of
the invention. In such a case, the objective indicia provide an unbiased
indication
<span CLASS="page_no" data-cite="688 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="688 F3d 1342">[*1371]</span> 
regarding the credibility of that evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the objective evidence strongly supports the jury's findings under
the first three <i>Graham</i> factors and cuts against the view that the claimed
inventions were an obvious combination of known elements from the prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On this record, S &amp; N has not proven by clear and convincing evidence that
the asserted claims are obvious. The district court committed error by
failing to defer to the <span CLASS="page_no" data-cite="104 uspq 2d 1021" data-cite-type="ReporterOfDecisions" data-cite-pageno="1021" data-primary-citation="104 U.S.P.Q.2d 1001">[**1021]</span> jury's factual findings and granting JMOL on
obviousness. Because the district court concluded that the other issues
raised in S &amp; N's motion for JMOL were moot in light of its decision to
grant JMOL on obviousness, we reverse and remand, so the district court can
consider those arguments in the first instance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>REVERSED AND REMANDED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Each party shall bear its own costs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The concurrence raises, and then purports to resolve, issues that were
neither raised nor discussed before the district court, and were not argued
in this appeal. Because it is about matters not before us, we do not respond
to the concurrence except to the extent our discussions of the patents and
the prior art already do so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> A "fistula" is generally considered to be a hole in an organ. <i>Kinetic</i>
<i>Concepts, Inc. v. Blue Sky Med. Grp., Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d 1010</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">1016</a>
(Fed.Cir.2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> KCI has not asserted this patent in the present litigation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> KCI did not appeal this judgment and is not, therefore, an appellant
before this court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> During oral argument, S &amp; N argued that this court's decision in
<i>Goodwall Construction Co. v. Beers Construction Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X30IC2?jcsearch=991%20f%202d%20751&amp;summary=yes#jcite">991 F.2d 751</a>
(Fed.Cir.1993) required it to file its motion under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3U003?jcsearch=Fed.%20R.%20Civ.%20P.%2050&amp;summary=yes#jcite">Rule 50</a> and not <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L42003?jcsearch=Fed.%20R.%20Civ.%20P.%2052(b)&amp;summary=yes#jcite">Rule
52(b)</a>. Oral Argument at 30:12-30:49, <i>Kinetic Concepts, Inc., v. Smith &amp;</i>
<i>Nephew, Inc.</i>, <cite>No.2011-1105</cite>, <i>available at</i>
http://www.cafc.uscourts.gov/oral-argument-recordings/<cite>2011-1105</cite>/all.
<i>Goodwall</i> does not address this issue, however. Instead, it addresses whether
a motion on an issue unresolved by the jury, which utilized a <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(a)&amp;summary=yes#jcite">Rule 49(a)</a>
special verdict form, is a motion for judgment under Rule 49(a) or <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3U003?jcsearch=Fed.%20R.%20Civ.%20P.%2050(b)&amp;summary=yes#jcite">Rule
50(b)</a>. <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X30IC2?jcsearch=991%20f%202d%20751&amp;summary=yes#jcite">991 F.2d at 756-57</a>. We held that it was a motion under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L3S003?jcsearch=Fed.%20R.%20Civ.%20P.%2049(a)&amp;summary=yes#jcite">Rule 49(a)</a>.
<i></i><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X30IC2?jcsearch=991%20F.2d%20at%20756-57&amp;summary=yes#jcite">Id. at 757</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> To the extent S &amp; N argues that KCI waived its right to a jury trial,
and agreed to use a <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X144L36003?jcsearch=Fed.%20R.%20Civ.%20P.%2039&amp;summary=yes#jcite">Rule 39</a>(c)(1) jury, we find no merit in this argument.
Waiver of the right to a jury trial cannot be assumed under circumstances in
which a party continually requests a jury trial and the district court never
referenced Rule 39 or waiver of the right to a jury trial when it referred
to an "advisory jury." <i>See Jennings v. McCormick</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36A13?jcsearch=154%20f%203d%20542&amp;summary=yes#jcite">154 F.3d 542</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X36A13?jcsearch=154%20f%203d%20542&amp;summary=yes#jcite">545</a> (5th
Cir.1998) ("The right to jury trial is too important and the usual procedure
for its waiver is too clearly set out by the Civil Rules for courts to find
a knowing and voluntary relinquishment of the right in a doubtful
situation." (citation omitted)); <i>McDonald v. Steward</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4Q4A3?jcsearch=132%20f%203d%20225&amp;summary=yes#jcite">132 F.3d 225</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4Q4A3?jcsearch=132%20f%203d%20225&amp;summary=yes#jcite">229</a> (5th
Cir.1998) ("Waiver should not be found in a doubtful situation." (internal
quotation and citation omitted)); <i>McAfee v. Martin</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X53NNK?jcsearch=63%20f%203d%20436&amp;summary=yes#jcite">63 F.3d 436</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X53NNK?jcsearch=63%20f%203d%20436&amp;summary=yes#jcite">437</a> (5th
Cir.1995) ("[C]ourts should indulge every reasonable presumption against
waiver." (internal quotation and citation omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> While the district court stated that the parties did not contest the
content of the prior art, this statement was incorrect. <i>JMOL Order</i> at 7.
Whether the prior art disclosed the treatment of wounds with negative
pressure was a key dispute between the parties, <i>see </i><cite>id. at 21</cite>, and the
district court resolved the issue in its JMOL order. <i></i><cite>Id. at 25</cite>, 27-28, 33.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> While the district court indicated in the <i>JMOL Order</i> that it was not
sure the claims contained this limitation, as explained below, they do. <i>See</i>
<i>infra</i> p. 1363.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> This is the same conclusion we reached in <i>Blue Sky</i> with respect to the
Chariker-Jeter references. <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1AGGAQ003?jcsearch=554%20f%203d%201010&amp;summary=yes#jcite">554 F.3d at 1020</a> ("[W]e find that the testimony
of KCI's witnesses was sufficient to allow the jury to reach the conclusion
that the Chariker-Jeter method was not used to 'treat a wound with negative
pressure' as required by the claims."). On this point, the evidence
presented in this case by Wake Forest and KCI was just as strong as the
evidence presented in <i>Blue Sky.</i> We, of course, base our conclusion on the
evidence in the current record.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> This conclusion is consistent with the PTO's determination on
reexamination that claims of the '<cite>651</cite> and '<cite>081 patents</cite> were patentable in
the face of some references at issue here. While this determination is not
binding on this court, the jury was informed of the results of the
reexamination and S &amp; N does not dispute the admissibility of this
evidence.
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DYK, Circuit Judge, concurring.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I agree with the majority that deference is owed to the jury's implied
findings in support of its nonobviousness verdict for the reasons ably set
forth in the majority opinion. However, I write separately because, in my
view, the majority errs in its construction of the "healing" limitations of
these claims. Because the jury was not properly instructed on claim
construction, it is impossible to determine what findings the jury made. At
the same time, because the accused infringer did not seek a construction of
the "healing" limitations, we should assume the jury used the correct
construction. Under this construction, there was not substantial evidence
that the claim limitations were absent from the prior art (though not in a
single reference) or that secondary considerations supported a finding of
non-obviousness, but there was substantial evidence for the jury to have
found insufficient motivation to combine. On this ground, I agree with the
majority that the accused infringer has not established invalidity for
obviousness as a matter of law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I Claim Construction
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the majority describes, the asserted claims cover an apparatus and
method for treating wounds by applying suction, or "negative pressure," and
Bagautdinov, Chariker-Jeter, and Zamierowski are three groups of prior art
that disclose similar suction treatment systems. The jury found that none of
the asserted claims would have been obvious over this prior art, but the
district court granted judgment as a matter of law ("JMOL") that all of the
asserted claims were invalid for obviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "It is elementary in patent law that, in determining whether a patent is
valid . . . the first step is to determine the meaning and scope of each
claim in suit." <i>Nat'l Steel Car, Ltd. v. Canadian Pac. Ry., Ltd.</i>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X6CV5J?jcsearch=357%20f%203d%201319&amp;summary=yes#jcite">357 F.3d 1319</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X6CV5J?jcsearch=357%20f%203d%201319&amp;summary=yes#jcite">1334</a> (Fed.Cir.2004) (quoting <i>Amazon.com, Inc. v.</i>
<i>Barnesandnoble.com, Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">239 F.3d 1343</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X50EPD?jcsearch=239%20f%203d%201343&amp;summary=yes#jcite">1351</a> (<span CLASS="page_no" data-cite="2012 bl 204409 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[***27]</span> Fed.Cir.2001)); <i>see also TI</i>
<i>Grp. Auto. Sys. (N. Am.), Inc. v. VDO N. Am., L.L.C.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEK10B?jcsearch=375%20f%203d%201126&amp;summary=yes#jcite">375 F.3d 1126</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEK10B?jcsearch=375%20f%203d%201126&amp;summary=yes#jcite">1139</a>
(Fed.Cir.2004) ("Our validity analysis is a two-step procedure: 'The first
step involves the proper interpretation of the claims.'") (quoting
<i>Beachcombers, Int'l, Inc. v. WildeWood Creative Prods., Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4M1TE?jcsearch=31%20f%203d%201154&amp;summary=yes#jcite">31 F.3d 1154</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4M1TE?jcsearch=31%20f%203d%201154&amp;summary=yes#jcite">1160</a> (Fed.Cir.1994)). The meaning of a claim is a purely
<span CLASS="page_no" data-cite="688 f 3d 1372" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1372" data-primary-citation="688 F3d 1342">[*1372]</span> 
legal issue, which we determine de novo. <i>See Cybor Corp. v. FAS Techs.,</i>
<i>Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">138 F.3d 1448</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X4Q5NA?jcsearch=138%20f%203d%201448&amp;summary=yes#jcite">1451</a> (Fed.Cir.1998). The majority disregards this well
established procedure by failing to directly address the proper construction
of the central claim limitations related to "healing."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority excuses its failure to do so on the ground that these claim
construction issues "were neither raised nor discussed before the district
court, and were not argued in this appeal." Maj. Op. at 1346 n. 1. I agree
with the majority that the parties have failed to address the claim
construction issues directly, and have chosen instead to address the issues
without the benefit of a proper claim construction. Nonetheless,
defendant-appellee Smith &amp; Nephew does contest the extent to which "healing"
is required by the claims, arguing that "Wake Forest attempted to redefine
its claimed invention throughout this litigation and continues to do so on
appeal" by "mischaracterize[ing] the claims as requiring 'active' treatment
of 'clean' wounds for 'extended' periods of time in order to heal the
wounds," even though "none of those limitations is in the claims."
Def.-Appellee's Br. 41.<a HREF="#fn101" name="fnref_fn101">[fn1]</a> And despite the parties' failure to seek a
proper construction of the "healing" limitations, it is simply not possible
to meaningfully address the question of obviousness without construing these
limitations either by making implicit assumptions about claim scope (as the
majority does) or by explicitly construing the claims (as I propose).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The asserted claims are claims 2 and 5 of <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=U.S.%20Patent%20No.%205,645,081&amp;summary=yes#jcite">U.S. Patent No. 5,645,081</a> ("the
'<cite>081 patent</cite>") and claims 42, 109, 116, and 121 of <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=U.S.%20Patent%20No.%207,216,651&amp;summary=yes#jcite">U.S. Patent No. 7,216,651</a>
("the '<cite>651 patent</cite>"). The '081 claims both require the apparatus to create
negative pressure "for facilitating the <i>healing</i> of wounds"<a HREF="#fn201" name="fnref_fn201">[fn2]</a> and to have
a "sealing means . . . for <i>maintaining</i> said negative pressure."'<span CLASS="page_no" data-cite="104 uspq 2d 1022" data-cite-type="ReporterOfDecisions" data-cite-pageno="1022" data-primary-citation="104 U.S.P.Q.2d 1001">[**1022]</span> <cite>081 Patent</cite>
col. 9 ll. 52-58 (emphases added). The asserted '651 method claims all
require "<i>maintaining</i>" negative pressure until the wound has "<i>progressed</i>
<i>toward a selected stage of healing.</i> "'<cite>651 Patent</cite> col. 23 l. 50, col. 25 ll.
47-48 (emphases added). The district court was not asked to construe
"maintaining," "healing," or "a selected stage of healing" (collectively,
"the 'healing' limitations"), but it did rule that the claims do not have a
minimum-time limitation, a construction not challenged on appeal. J.A.
13390. We are unable to determine whether the asserted claims are obvious as
a matter of law without understanding the meaning of these "healing"
limitations. Because these claim terms are central to these appeal, our
obligation to construe these limitations cannot be avoided simply because
the district court failed to do so.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In my view, the "healing" limitations are properly construed as requiring
only some progress toward healing &mdash; for example, the formation of some new
tissue or skin &mdash; and <span CLASS="page_no" data-cite="2012 bl 204409 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[***28]</span> not complete healing or wound closure. The language of
the "selected stage of healing" limitation itself clearly indicates that
only some progress toward healing is required. Additionally, claim 20 of the
'<cite>651 patent</cite> (upon which claims 109, 116, and 121 depend) refers to
"maintaining
<span CLASS="page_no" data-cite="688 f 3d 1373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1373" data-primary-citation="688 F3d 1342">[*1373]</span> 
reduced pressure to promote the formation of granulation tissue," and claim
121 specifies that "the selected stage of healing comprises
re-epithelialization of at least a portion of the wound."'<cite>651 Patent</cite> col. 23
ll. 48-49, col. 30 ll. 30-31. The district court construed "granulation
tissue" as "tissue formed during wound healing" and "re-epithelialization"
as "re-growth of skin." J.A. 10373, 10377 (emphases omitted). Neither party
objected to these constructions on appeal. These additional limitations in
claims 20 and 121 demonstrate that "a selected stage of healing" cannot
refer to complete healing. Furthermore, the unasserted dependent claims
118-120 and 122-124 of the '<cite>651 patent</cite> provide other more restrictive
examples of "selected stage[s] of healing": "substantial closure of the
wound," "substantially filling the wound with granulation tissue,"
"migration of epithelial and subcutaneous tissue toward the wound," and "a
reduction in the volume [diameter or depth] of the wound by a predetermined
amount." Under the "presumption that an independent claim should not be
construed as requiring a limitation added by a dependent claim,"
<i>Curtiss-Wright Flow Control Corp. v. Velan, Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1455N8003?jcsearch=438%20f%203d%201374&amp;summary=yes#jcite">438 F.3d 1374</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1455N8003?jcsearch=438%20f%203d%201374&amp;summary=yes#jcite">1380</a>
(Fed.Cir.2006), "a selected stage of healing" is presumed to not include
these limitations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is also no indication in the specifications that "healing" or
"selected stage of healing" refers to any particular stage of healing; the
'<cite>651 patent</cite> simply notes that "[a]n initial stage of wound healing is
characterized by the formation of granulation tissue" and that "[a] selected
state of improved condition may include" a number of conditions, including
any "stages of improvement or healing appropriate to a given type of wound
or wound complex."'<cite>651 Patent</cite> col. 1 ll. 40-41, col. 12 ll. 59-66. The '<cite>081
patent</cite> does not define "facilitating . . . healing" (as used in the claim
preambles), but it notes that the invention may be used to "promote the
migration of . . . tissue," "reduce bacterial density in a wound," or
"prevent[] the infection [in a burn wound] from becoming [too] severe,"
"facilitating . . . healing." '<cite>081 Patent</cite> col. 1 ll. 57-58, col. 2 ll. 1-2,
col. 3 l. 67-col. 4 l. I.<a HREF="#fn301" name="fnref_fn301">[fn3]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although the majority opinion does not explicitly construe the "healing"
limitations, it seems to make three assumptions as to the meaning of these
limitations. First, the majority suggests that the claims require
application of negative pressure for a particular extended length of time.
For example, the majority explains that Bagautdinov did not sustain pressure
"for a long enough period of time" and taught away from applying negative
pressure "for extended periods"; and that Chariker-Jeter taught "away from
continued long-term use of the device, as directed by the '<cite>081</cite> and '<cite>651
patents</cite>." Maj. Op. at 1362, 1365. But as discussed above, the district court
correctly <span CLASS="page_no" data-cite="2012 bl 204409 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[***29]</span> determined that the claims do not have a minimum time limitation,
and that construction is not challenged on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, to some extent, the majority suggests that the claims require more
than some progress toward healing, such as complete healing or closure. For
example,
<span CLASS="page_no" data-cite="688 f 3d 1374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1374" data-primary-citation="688 F3d 1342">[*1374]</span> 
the majority states that "the invention applies 'negative pressure . . . for
a time sufficient to facilitate <i>closure</i> of the wound,'" that Bagautdinov was
different from the claimed invention because it was not used "to treat
wounds <i>until closure</i>," and that the asserted claims "require wounds to be
<i>heeded</i> by negative pressure." Maj. Op. at 1346-47, 1363 (emphases added). To
the <span CLASS="page_no" data-cite="104 uspq 2d 1023" data-cite-type="ReporterOfDecisions" data-cite-pageno="1023" data-primary-citation="104 U.S.P.Q.2d 1001">[**1023]</span> extent the majority reads a requirement of complete closure into the
claims, this seems to me to be incorrect &mdash; as discussed above, the "healing"
limitations merely require some progress toward healing, such as the
formation of granulation tissue or regrowth of skin.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Third, the majority seems to suggest that the prior art was different from
the claimed invention because the <i>purpose</i> of the prior art was drainage and
cleaning, rather than healing. The majority explains that Bagautdinov was
"for draining fluid" and was "discontinued when the purulent wound has been
cleaned"; that Zamierowski is "used to either drain from or inject fluid
into the wound" and was not used "for wound therapy"; and that
Chariker-Jeter was a "drainage system" that was "discontinued when the
fistula closed or substantial drainage from the fistula stopped." Maj. Op.
1362, 1364, 1365. However, the claims do not contain a purpose requirement &mdash;
it is enough that healing is disclosed by the prior art, even if this was
not the intention of the prior art inventors. As the Supreme Court
explained, "[i]n determining whether the subject matter of a patent claim is
obvious, neither the particular motivation nor the avowed purpose of the
patentee controls. What matters is the objective reach of the claim. If the
claim extends to what is obvious, it is invalid under <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a>." <i>KSR Int'l Co.</i>
<i>v. Teleflex Inc.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">419</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007);
<i>see also Nat'l Steel Car, Ltd. v. Canadian Pac. Ry., Ltd.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X6CV5J?jcsearch=357%20f%203d%201319&amp;summary=yes#jcite">357 F.3d 1319</a>,
<a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X6CV5J?jcsearch=357%20f%203d%201319&amp;summary=yes#jcite">1339</a> (Fed.Cir.2004) ("A finding that two inventions were designed to resolve
different problems . . . is insufficient to demonstrate that one invention
teaches away from another."); <i>In re Beattie</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3ACQ3?jcsearch=974%20f%202d%201309&amp;summary=yes#jcite">974 F.2d 1309</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X3ACQ3?jcsearch=974%20f%202d%201309&amp;summary=yes#jcite">1312</a>
(Fed.Cir.1992) ("[T]he law does not require that the references be combined
for the reasons contemplated by the inventor."). It is irrelevant that the
prior art had the purpose of drainage as long as it used negative pressure
to heal wounds within the meaning of the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As discussed below, the majority's erroneous claim construction leads it
to incorrectly conclude that the claim limitations are not found in the
prior art and that secondary considerations supported a finding of
non-obviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II Limitations Present in the Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the correct claim construction, contrary to the majority, the claim
limitations are disclosed in the prior art. Because the jury received no
instruction on the meaning of the "healing" limitations, it is impossible to
determine whether the jury's findings in support of its nonobviousness
<span CLASS="page_no" data-cite="2012 bl 204409 p 30" data-cite-type="Bloomberg" data-cite-pageno="30" data-primary-citation="">[***30]</span> verdict were based on the correct construction.<a HREF="#fn401" name="fnref_fn401">[fn4]</a> However, the party
challenging validity, Smith &amp; Nephew, did not seek a jury instruction on the
"healing" limitations. "[L]itigants waive their right to present new claim
construction disputes if they are raised for the first time after trial."
<i>Cordis Corp. v. Boston Scientific Corp.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1ARNEU003?jcsearch=561%20f%203d%201319&amp;summary=yes#jcite">561 F.3d 1319</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1ARNEU003?jcsearch=561%20f%203d%201319&amp;summary=yes#jcite">1331</a> (Fed.Cir.2009)

(<span CLASS="page_no" data-cite="688 f 3d 1375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1375" data-primary-citation="688 F3d 1342">[*1375]</span> quoting <i>Conoco, Inc. v. Energy &amp; Envtl. Int'l, L.C.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">460 F.3d 1349</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">1359</a>
(Fed.Cir.2006)). We therefore should assume that the jury used the correct
claim construction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the proper construction, the Bagautdinov, Chariker-Jeter, and
Zamierowski groups of prior art all meet the limitations of "maintaining"
negative pressure "for . . . healing" or until a "selected stage of healing"
because they explicitly disclose the regrowth of tissue and skin (i.e., the
formation of granulation tissue and re-epithelialization). The Bagautdinov
method "accelerates . . . sealing of purulent wounds," and "the appearance
of granulated tissue" was seen around the fourth or fifth day of vacuum
treatment. J.A. 10003, 10027. One of the Chariker-Jeter publications states
that "an increased rate of granulation and re-epithelialization is seen with
the closed suction wound drainage system." J.A. 10051. And Zamierowski
states that it "promotes healing" and that "the present invention is
particularly well adapted for the . . . regeneration of skin graft donor
sites." J.A. 10063, 10067.<a HREF="#fn501" name="fnref_fn501">[fn5]</a> Because each of these references applied
negative pressure for "healing" within the meaning of the claims, it is
irrelevant whether these references teach away from more prolonged
application of negative pressure. There is no substantial evidence to the
contrary. The majority errs in concluding that <span CLASS="page_no" data-cite="104 uspq 2d 1024" data-cite-type="ReporterOfDecisions" data-cite-pageno="1024" data-primary-citation="104 U.S.P.Q.2d 1001">[**1024]</span> these claim limitations were
not present in the prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III Secondary Considerations
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority also errs, in my view, in finding that the jury could
properly rely on secondary considerations to find the claims non-obvious.
The failure to construe the "healing" limitations affects not only the prima
facie case of obviousness, but also the analysis of secondary
considerations, as we cannot determine whether the jury's findings of
secondary considerations were based on a proper understanding of claim
scope. "Evidence of secondary considerations must be reasonably commensurate
with the scope of the claims." <i>In re Hum-Hung Kao</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FEUP6003?jcsearch=639%20f%203d%201057&amp;summary=yes#jcite">639 F.3d 1057</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1FEUP6003?jcsearch=639%20f%203d%201057&amp;summary=yes#jcite">1068</a>
(Fed.Cir.2011). Secondary considerations related to a patentee's commercial
product is not probative of nonobviousness if the asserted claims are far
broader than that commercial embodiment. Here, as the majority notes, there
was substantial evidence that the patentee's product (1) was a commercial
success; (2) was responsive to a long-felt need; (3) was copied by others;
(4) had unexpected results; (5) was accepted by others; and (6) faced
initial skepticism. Maj. Op. at 1367. These secondary considerations,
however, were related to the use of the commercial device utilizing the
patent for extended periods to close and completely heal wounds.<a HREF="#fn601" name="fnref_fn601">[fn6]</a> This
evidence would clearly be relevant if the patent claims were limited to
complete healing or wound closure, but as discussed <span CLASS="page_no" data-cite="2012 bl 204409 p 31" data-cite-type="Bloomberg" data-cite-pageno="31" data-primary-citation="">[***31]</span> above, the
<span CLASS="page_no" data-cite="688 f 3d 1376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1376" data-primary-citation="688 F3d 1342">[*1376]</span> 
claims require only some progress toward healing. There was no substantial
evidence that there were secondary considerations relevant to the invention
as set forth in the claims as opposed to the far narrower commercial
embodiment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV Motivation to Combine
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the majority describes, there is, however, substantial evidence that
Bagautdinov and Chariker-Jeter treat pus pockets and fistulae, respectively,
rather than "wounds," and that Bagautdinov, Zamierowski, and the
Chariker-Jeter public use do not disclose an adequate seal. Thus, at the
very least, to find obviousness, a person of ordinary skill would have
needed a motivation to combine the treatment of "wounds" by Zamierowski with
the seal from the Chariker-Jeter publications. While motivation to combine
may be addressed on summary judgment or JMOL in appropriate circumstances,
<i>see Wyers v. Master Lock Co.</i>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">616 F.3d 1231</a>, <a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1DMPC6003?jcsearch=616%20f%203d%201231&amp;summary=yes#jcite">1240</a> (Fed.Cir.2010), it is
still a question of fact, and the accused infringers have failed to show
that there was not substantial evidence to support a finding of insufficient
motivation to combine. In other words, under the assumption that the jury
used the correct construction of the "healing" limitations, there is
substantial evidence for the jury to have at least found the asserted claims
non-obvious due to insufficient motivation to combine. Thus, I agree with
the majority's ultimate conclusion that the district court erred in granting
JMOL of obviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> Smith &amp; Nephew also raises the argument that "there is a lack of
substantial evidence to support the jury's finding of nexus between the '081
claims and the secondary considerations." <i></i><cite>Id. at 66</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> The accused infringer appears to agree that this preamble language is
a claim limitation. <i>See</i> Def.-Appellee's Br. 62 ("The '081 claims merely
require an apparatus that <i>facilitates</i> the healing of wounds.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> While the patent does mention that the invention includes application
of negative pressure "for a time sufficient to facilitate closure of the
wound," <i><cite>id</cite>.</i> col. 2 ll. 48-49, it nowhere suggests that "healing" is
synonymous with "closure," or that "facilitat[ing] closure" requires the
application of negative pressure until closure. As noted the patentee did
not challenge the court's construction that there is no time limit in the
claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> The jury did answer some specific questions in addition to giving a
general verdict of nonobviousness, <i>see</i> J.A. 65-70, but none of those
specific questions is relevant to this issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn501" name="fn501">[fn5]</a></span> The majority's suggestion that Zamierowski "failed to disclose
maintaining negative pressure until the wound has progressed to a selected
stage of healing," Maj. Op. at 1363, is thus incorrect; the majority cites
testimony that merely states that Zamierowski does not discuss granulation
tissue formation. <i>See</i> J.A. 22457:15-19 (Q. "It follows, from the fact that
he doesn't mention granulation, that he's not stating that he promotes
granulation tissue growth?" A. "Well . . . he doesn't state: My device
promotes granulation tissue."); J.A. 22669:5-8 ("[H]e really does not talk
about the healing, maintaining the pressure until the wound has progressed
to the selected stage of healing. He doesn't talk about granulation tissue
formation, promotion of that.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn601" name="fn601">[fn6]</a></span> For example, Dr. Argenta, an inventor on the patents, testified that
he was surprised when a patient with a serious wound "<i>heal[ed] completely</i>"
after several months of treatment. J.A. 20446:22 (emphasis added). Another
expert testified that when a patient with an ulcer that would not heal was
healed after eight weeks of treatment, he was "stunned" "[b]ecause we had
used the best techniques we knew to date <i>to close this wound</i> and none had
worked and this technique, which was counterintuitive, worked." J.A.
22828:23-22829:2 (emphasis added).
</p></div>
<!--BBLS DD 1721688195075-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I3E9Q003/history">Direct History (1)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I3E9Q003/analysis">Case Analysis (22)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I3E9Q003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
22
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Reversed, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Procedures</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/document/X1Q6LG1HHE82">11-01105 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/6fbf8c218bec0e89de0d86ac94c15f96/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "6fbf8c218bec0e89de0d86ac94c15f96";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY042e47&previousPageId=&previousActivityInstanceId=ENTITY5f8829&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:14:32-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I3E9Q003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY5f8829&previousPageId=&previousActivityInstanceId=ENTITYb79e24&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:14:20-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I3E9Q003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I3E9Q003";
$('#page_loader').show().spin();
JUDGE_IDS=["3027440","3057465","3408847"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
